[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2989
6. Hsiung PL, Wang T: In vivo biomarkers for targeting colorectal neoplasms. Cancer Biomark; 2008;4(6):329-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Colorectal Neoplasms / diagnosis. Molecular Probe Techniques

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2003 Nov;98(11):2543-9 [14638361.001]
  • [Cites] Nat Med. 2008 Apr;14(4):454-8 [18345013.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1564-71 [15051756.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3069-75 [15131045.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6247-51 [15342411.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Oct;2(10):905-11 [15476154.001]
  • [Cites] Nature. 1987 Aug 27-Sep 2;328(6133):820-3 [3498122.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Science. 1992 May 1;256(5057):668-70 [1350108.001]
  • [Cites] Cancer. 1992 Sep 15;70(6 Suppl):1727-31 [1516027.001]
  • [Cites] Cancer Res. 1995 Sep 15;55(18):3964-8 [7664263.001]
  • [Cites] Gastrointest Endosc. 1996 Jul;44(1):15-22 [8836711.001]
  • [Cites] Nature. 1997 Apr 10;386(6625):623-7 [9121588.001]
  • [Cites] Breast Cancer Res Treat. 1997 Aug;45(1):29-37 [9285114.001]
  • [Cites] Nat Biotechnol. 1997 Nov;15(12):1271-5 [9359110.001]
  • [Cites] Q J Nucl Med. 1998 Mar;42(1):33-42 [9646643.001]
  • [Cites] Br J Cancer. 1998 Nov;78(10):1379-84 [9823983.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):123-7 [9916805.001]
  • [Cites] Nat Biotechnol. 1999 Apr;17(4):375-8 [10207887.001]
  • [Cites] Immunol Rev. 1999 Jun;169:195-207 [10450518.001]
  • [Cites] Oncogene. 1999 Sep 20;18(38):5325-33 [10498885.001]
  • [Cites] J Vasc Res. 2004 Sep-Oct;41(5):400-11 [15467299.001]
  • [Cites] Dis Colon Rectum. 2004 Nov;47(11):1904-14 [15622584.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3526-35 [15908663.001]
  • [Cites] Gastroenterology. 2005 Sep;129(3):874-84 [16143127.001]
  • [Cites] Oncogene. 2005 Sep 8;24(40):6155-64 [16091735.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):521-8 [16185965.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9200-5 [16230380.001]
  • [Cites] Dis Colon Rectum. 2005 Dec;48(12):2238-48 [16228831.001]
  • [Cites] J Mol Diagn. 2006 Feb;8(1):68-75 [16436636.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):343-50 [16454841.001]
  • [Cites] Ann Surg Oncol. 2006 Jun;13(6):823-35 [16614884.001]
  • [Cites] Ann Surg Oncol. 2006 Aug;13(8):1021-34 [16897272.001]
  • [Cites] Neoplasia. 2006 Sep;8(9):772-80 [16984734.001]
  • [Cites] Gastrointest Endosc. 2006 Oct;64(4):589-97 [16996355.001]
  • [Cites] Cancer. 2006 Oct 1;107(7):1624-33 [16933324.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9804-8 [17047040.001]
  • [Cites] Oncologist. 2007 Apr;12(4):443-50 [17470687.001]
  • [Cites] Dis Colon Rectum. 2007 Jun;50(6):839-55 [17308939.001]
  • [Cites] Radiology. 2007 Jul;244(1):232-8 [17507718.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9721-30 [17942902.001]
  • [Cites] Endoscopy. 1999 Sep;31(7):511-6 [10533733.001]
  • [Cites] J Cell Biochem Suppl. 2000;34:28-34 [10762012.001]
  • [Cites] Am J Gastroenterol. 2000 Apr;95(4):1062-7 [10763960.001]
  • [Cites] Nature. 2000 Apr 27;404(6781):1003-7 [10801130.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2803-7 [10914727.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Nov;5(11):1300-5 [17936692.001]
  • [Cites] N Engl J Med. 2007 Nov 15;357(20):2040-8 [18003960.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):854-65 [10982779.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4953-8 [10987312.001]
  • [Cites] Nat Med. 2001 Jun;7(6):743-8 [11385514.001]
  • [Cites] Cell. 2002 Jan 25;108(2):135-44 [11832204.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):406-14 [11832455.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):251-65 [12001987.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2002 Jul;12(3):495-523 [12486941.001]
  • [Cites] Eur J Cancer. 2003 May;39(8):1041-52 [12736102.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 May;129(5):263-71 [12750996.001]
  • [Cites] Surg Oncol. 2007 Dec;16 Suppl 1:S93-6 [18257148.001]
  • [Cites] Nat Methods. 2008 Mar;5(3):231-3 [18264107.001]
  • [Cites] JAMA. 2008 Mar 5;299(9):1027-35 [18319413.001]
  • [Cites] Clin Ther. 2008 Jan;30(1):14-30 [18343240.001]
  • [Cites] Mol Imaging. 2003 Oct;2(4):350-7 [14717334.001]
  • (PMID = 19126961.001).
  • [ISSN] 1574-0153
  • [Journal-full-title] Cancer biomarkers : section A of Disease markers
  • [ISO-abbreviation] Cancer Biomark
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK067618; United States / NIDDK NIH HHS / DK / K08 DK067618-06; United States / NIDDK NIH HHS / DK / R03 DK075603; United States / NIDDK NIH HHS / DK / R03 DK075603-03; United States / NCI NIH HHS / CA / R33 CA109988; United States / NCI NIH HHS / CA / R33 CA109988-05; United States / NCI NIH HHS / CA / U54 CA136429; United States / NCI NIH HHS / CA / U54 CA136429-05
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 68
  • [Other-IDs] NLM/ NIHMS336978; NLM/ PMC3232019
  •  go-up   go-down


7. Qin LQ, Xu JY, Tezuka H, Li J, Arita J, Hoshi K, Sato A: Consumption of commercial whole and non-fat milk increases the incidence of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats. Cancer Detect Prev; 2007;31(4):339-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Breast cancer has become the most common cancer among women worldwide.
  • Although the consumptions of milk and dairy products were considered to be a risk factor for breast cancer in some epidemiological studies, the results were inconsistent.
  • [MeSH-major] Adenocarcinoma / etiology. Dietary Fats / adverse effects. Mammary Neoplasms, Experimental / etiology. Milk / adverse effects

  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17935906.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dietary Fats; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  •  go-up   go-down


8. Piedbois P, Serin D, Priou F, Laplaige P, Greget S, Angellier E, Teissier E, Berdah JF, Fabbro M, Valenza B, Herait P, Jehl V, Buyse M: Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Ann Oncol; 2007 Jan;18(1):52-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study.
  • PATIENTS AND METHODS: Ninety-nine patients with node-positive invasive breast adenocarcinoma were randomly assigned to docetaxel (Taxotere) (T) 75 mg/m2, epirubicin (E) 75 mg/m2 and cyclophosphamide (C) 500 mg/m2 (TEC)x6, every 3 weeks; E 100 mg/m2, C 600 mg/m2 x 4, then T 100 mg/m2 x 4 (EC-->T) or the reverse sequence (T-->EC), every 2 weeks, with pegfilgrastim support.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2008 May;19(5):1019; author reply 1019-20 [18325914.001]
  • (PMID = 17047001.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


9. Frigo DE, Basu A, Nierth-Simpson EN, Weldon CB, Dugan CM, Elliott S, Collins-Burow BM, Salvo VA, Zhu Y, Melnik LI, Lopez GN, Kushner PJ, Curiel TJ, Rowan BG, McLachlan JA, Burow ME: p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1. Mol Endocrinol; 2006 May;20(5):971-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we demonstrate that the p38 MAPK stimulates both ERalpha- and ERbeta-mediated transcription in MCF-7 breast carcinoma, Ishikawa endometrial adenocarcinoma, and human embryonic kidney 293 cells.

  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410316.001).
  • [ISSN] 0888-8809
  • [Journal-full-title] Molecular endocrinology (Baltimore, Md.)
  • [ISO-abbreviation] Mol. Endocrinol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK059389; United States / PHS HHS / / R06/CCR419466-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Estrogens; 0 / Imidazoles; 0 / NCOA2 protein, human; 0 / Nuclear Receptor Coactivator 2; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / RWJ 67657; EC 2.7.1.- / MAP2K6 protein, human; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 2.7.12.2 / MAP Kinase Kinase 6
  •  go-up   go-down


10. Gutmann EJ, Cates JM: Initial diagnosis of breast cancer via cytological examination of a pleural effusion: a rare event facilitated by recognition of an unusual morphological pattern. Diagn Cytopathol; 2005 Mar;32(3):177-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial diagnosis of breast cancer via cytological examination of a pleural effusion: a rare event facilitated by recognition of an unusual morphological pattern.
  • It is uncommon for breast carcinoma to present as a malignant serous effusion.
  • Here, we describe a case in which the initial diagnosis of an occult invasive ductal carcinoma of the breast was made via cytological examination of a pleural effusion.
  • Recognition of a cribriform architecture with intraluminal necrosis and microcalcifications in a cell block preparation was critical in making that diagnosis.
  • To our knowledge, this specific morphological pattern of breast carcinoma in a cell block preparation from an effusion has not been reported previously.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Aged. Biopsy, Needle. Diagnosis, Differential. Dyspnea / etiology. Female. Humans. Lung Neoplasms / diagnosis. Pleural Effusion, Malignant / pathology. Pulmonary Disease, Chronic Obstructive / complications

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15690336.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Jahchan NS, You YH, Muller WJ, Luo K: Transforming growth factor-beta regulator SnoN modulates mammary gland branching morphogenesis, postlactational involution, and mammary tumorigenesis. Cancer Res; 2010 May 15;70(10):4204-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transforming growth factor-beta regulator SnoN modulates mammary gland branching morphogenesis, postlactational involution, and mammary tumorigenesis.
  • SnoN is an important negative regulator of transforming growth factor-beta (TGF-beta) signaling that was originally identified as a transforming oncogene in chicken embryonic fibroblasts.
  • Both pro-oncogenic and antioncogenic activities of SnoN have been reported, but its function in normal epithelial cells has not been defined.
  • In the mouse mammary gland, SnoN is expressed at relatively low levels, but it is transiently upregulated at late gestation before being downregulated during lactation and early involution.
  • To assess the effects of elevated levels of SnoN, we generated transgenic mice expressing a SnoN fragment under the control of the mouse mammary tumor virus promoter.
  • In this model system, SnoN elevation increased side-branching and lobular-alveolar proliferation in virgin glands, while accelerating involution in postlactation glands.
  • Increased proliferation stimulated by SnoN was insufficient to induce mammary tumorigenesis.
  • In contrast, elevated levels of SnoN cooperated with polyoma middle T antigen to accelerate the formation of aggressive multifocal adenocarcinomas and to increase the formation of pulmonary metastases.
  • Our studies define functions of SnoN in mammary epithelial cell proliferation and involution, and provide the first in vivo evidence of a pro-oncogenic role for SnoN in mammalian tumorigenesis.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2010 AACR.
  • [Cites] Mol Cell Biol. 2003 Aug;23(15):5446-59 [12861029.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):1809-19 [18339861.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1539-49 [14507660.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):577-84 [14534577.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):919-28 [14601051.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):807-21 [14557817.001]
  • [Cites] Nucleic Acids Res. 1989 Jul 25;17(14):5489-500 [2762147.001]
  • [Cites] Mol Cell Biol. 1992 Mar;12(3):954-61 [1312220.001]
  • [Cites] Development. 1991 Nov;113(3):867-78 [1821856.001]
  • [Cites] Oncogene. 1993 Feb;8(2):457-66 [8426750.001]
  • [Cites] Nucleic Acids Res. 1993 Sep 25;21(19):4632-8 [8233802.001]
  • [Cites] Genes Dev. 1993 Dec;7(12A):2308-17 [8253379.001]
  • [Cites] Genes Dev. 1994 Jan;8(1):23-32 [7507074.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4254-8 [7753792.001]
  • [Cites] J Gen Virol. 1997 Apr;78 ( Pt 4):893-903 [9129663.001]
  • [Cites] Nucleic Acids Res. 1997 Jul 15;25(14):2930-7 [9207045.001]
  • [Cites] Cell Growth Differ. 1998 Mar;9(3):229-38 [9543389.001]
  • [Cites] Genes Dev. 1999 Sep 1;13(17):2196-206 [10485843.001]
  • [Cites] EMBO J. 2009 Nov 18;28(22):3500-13 [19745809.001]
  • [Cites] Mol Cell Biol. 2005 Dec;25(24):10731-44 [16314499.001]
  • [Cites] Science. 1999 Oct 22;286(5440):771-4 [10531062.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12442-7 [10535941.001]
  • [Cites] J Biol Chem. 1999 Dec 3;274(49):35269-77 [10575014.001]
  • [Cites] Cell Growth Differ. 2000 Jan;11(1):31-9 [10672901.001]
  • [Cites] EMBO J. 2000 Apr 17;19(8):1745-54 [10775259.001]
  • [Cites] EMBO J. 2000 May 15;19(10):2280-91 [10811619.001]
  • [Cites] Nat Cell Biol. 2001 Jun;3(6):587-95 [11389444.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Jan;6(1):67-82 [11467453.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Aug 24;286(3):559-65 [11511096.001]
  • [Cites] Genes Dev. 2001 Nov 1;15(21):2822-36 [11691834.001]
  • [Cites] Cell Growth Differ. 2002 Mar;13(3):123-30 [11959813.001]
  • [Cites] Immunol Lett. 2002 Jun 3;82(1-2):85-91 [12008039.001]
  • [Cites] Science. 2002 May 31;296(5573):1646-7 [12040180.001]
  • [Cites] Cell. 2002 Nov 1;111(3):357-67 [12419246.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3123-9 [12793438.001]
  • [Cites] J Cell Sci. 2003 Jul 15;116(Pt 14):2975-86 [12808020.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8430-5 [12808151.001]
  • [Cites] Genes Dev. 1999 Oct 1;13(19):2604-16 [10521404.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2296-302 [15781643.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4782-8 [15930298.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12437-42 [16109768.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8617-21 [16204027.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Sep;6(9):715-25 [16231422.001]
  • [Cites] Breast Cancer Res. 2006;8(1):201 [16524451.001]
  • [Cites] Oncogene. 2006 Jun 8;25(24):3408-23 [16186809.001]
  • [Cites] Nat Rev Cancer. 2006 Jul;6(7):506-20 [16794634.001]
  • [Cites] Breast Cancer Res. 2006;8(2):203 [16677411.001]
  • [Cites] Mol Cell Biol. 2007 Jan;27(1):324-39 [17074815.001]
  • [Cites] Dev Biol. 2007 Jun 1;306(1):193-207 [17448457.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5005-10 [12941827.001]
  • (PMID = 20460516.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA087940-07; United States / NCI NIH HHS / CA / R01 CA087940; United States / NCI NIH HHS / CA / R01 CA101891; United States / NCI NIH HHS / CA / R01 CA087940-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / SKIL protein, human; 0 / Transforming Growth Factor beta
  • [Other-IDs] NLM/ NIHMS280569; NLM/ PMC3098116
  •  go-up   go-down


12. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, Yu S, Stephens LC, Cui X, Murrow G, Coombes K, Muller W, Hung MC, Perou CM, Lee AV, Fang X, Mills GB: Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell; 2009 Jun 2;15(6):539-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the role of ATX and LPA receptors in the initiation and progression of breast cancer has not been evaluated.
  • Thus, ATX and LPA receptors can contribute to the initiation and progression of breast cancer.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cancer Ther. 2007 Apr;6(4):1414-24 [17431120.001]
  • [Cites] Cell. 2007 Jun 15;129(6):1111-23 [17574024.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3207-14 [17545524.001]
  • [Cites] Int J Oncol. 2007 Aug;31(2):441-9 [17611702.001]
  • [Cites] Genome Biol. 2007;8(5):R76 [17493263.001]
  • [Cites] Bioinformatics. 2007 Aug 1;23(15):1986-94 [17599930.001]
  • [Cites] Cell. 2007 Aug 24;130(4):597-600 [17719538.001]
  • [Cites] J Biol Chem. 2007 Sep 14;282(37):27229-38 [17652082.001]
  • [Cites] Ann N Y Acad Sci. 2000 Apr;905:188-208 [10818454.001]
  • [Cites] Mod Pathol. 2001 May;14(5):458-64 [11353057.001]
  • [Cites] J Natl Cancer Inst. 2001 May 16;93(10):762-8 [11353786.001]
  • [Cites] J Cell Biol. 2002 Jul 22;158(2):227-33 [12119361.001]
  • [Cites] J Biol Chem. 2002 Aug 16;277(33):29584-92 [12048217.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11187-92 [12169667.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1706-11 [12670925.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(16):5738-54 [12897145.001]
  • [Cites] Bioinformatics. 2004 Jan 1;20(1):105-14 [14693816.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9653-61 [14670967.001]
  • [Cites] J Cell Biochem. 2004 Aug 15;92(6):1115-40 [15258897.001]
  • [Cites] Bioessays. 2004 Aug;26(8):870-81 [15273989.001]
  • [Cites] Cell. 1987 May 22;49(4):465-75 [3032456.001]
  • [Cites] Cell. 1989 Oct 6;59(1):45-54 [2551506.001]
  • [Cites] Science. 1991 Jul 5;253(5015):49-53 [1905840.001]
  • [Cites] Mol Cell Biol. 1994 May;14(5):3186-96 [8164674.001]
  • [Cites] Biochem J. 1995 Aug 1;309 ( Pt 3):933-40 [7639713.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):4987-91 [9371488.001]
  • [Cites] Lipids. 1999 Jan;34(1):17-21 [10188592.001]
  • [Cites] Cell. 1999 Aug 6;98(3):295-303 [10458605.001]
  • [Cites] Oncogene. 1999 Aug 12;18(32):4564-76 [10467401.001]
  • [Cites] Breast Cancer Res. 2004;6(6):R640-6 [15535846.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):51075-81 [15466414.001]
  • [Cites] J Clin Invest. 2004 Dec;114(12):1714-25 [15599396.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):211-7 [15766659.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6027-32 [15837931.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3781-7 [15867374.001]
  • [Cites] Oncogene. 2005 Jun 16;24(26):4220-31 [15824740.001]
  • [Cites] Nat Rev Drug Discov. 2005 Dec;4(12):988-1004 [16341064.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 15;98(4):262-72 [16478745.001]
  • [Cites] Drug Discov Today. 2006 Jun;11(11-12):481-93 [16713899.001]
  • [Cites] Mol Cell Biol. 2006 Jul;26(13):5015-22 [16782887.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9643-8 [16769891.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):22786-93 [16782709.001]
  • [Cites] Mol Cancer Ther. 2006 Oct;5(10):2512-21 [17041095.001]
  • [Cites] Mol Cell Biol. 2006 Dec;26(24):9302-14 [17030631.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cell Cycle. 2007 Mar 15;6(6):667-71 [17361100.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8494-503 [17875688.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):395-402 [17936563.001]
  • [Cites] Expert Rev Mol Med. 2007;9(28):1-18 [17935635.001]
  • [Cites] Mol Cancer Res. 2007 Nov;5(11):1201-11 [18025263.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11751-9 [18089805.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5248-53 [18367674.001]
  • [Cites] Nat Med. 2008 May;14(5):518-27 [18438415.001]
  • [Cites] J Biol Chem. 2008 Jun 13;283(24):16818-29 [18408217.001]
  • [Cites] J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42 [19001604.001]
  • [Cites] Oncogene. 2008 Nov 20;27(54):6806-16 [18762810.001]
  • [Cites] J Biol Chem. 2009 Mar 13;284(11):7385-94 [19139100.001]
  • [Cites] J Biol Chem. 2005 Mar 11;280(10):9498-508 [15618220.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 May;292(5):C1927-33 [17496233.001]
  • [Cites] Biochim Biophys Acta. 2007 Jul;1771(7):883-92 [17531530.001]
  • [CommentIn] Cancer Cell. 2009 Jun 2;15(6):457-9 [19477423.001]
  • [ErratumIn] Cancer Cell. 2009 Aug 4;16(2):172
  • (PMID = 19477432.001).
  • [ISSN] 1878-3686
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE15263
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P01 CA064602; United States / NCI NIH HHS / CA / CA099031; United States / NCI NIH HHS / CA / P30CA016672; United States / NCI NIH HHS / CA / P50 CA098258; United States / NCI NIH HHS / CA / CA64602; United States / NCI NIH HHS / CA / R01 CA082716; United States / NCI NIH HHS / CA / P01 CA099031; United States / NCI NIH HHS / CA / R01 CA094118; United States / NCI NIH HHS / CA / CA82716
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Multienzyme Complexes; 0 / Receptors, Estrogen; 0 / Receptors, Lysophosphatidic Acid; EC 3.1.4.- / Phosphoric Diester Hydrolases; EC 3.1.4.1 / Phosphodiesterase I; EC 3.1.4.39 / alkylglycerophosphoethanolamine phosphodiesterase; EC 3.6.1.- / Pyrophosphatases
  • [Other-IDs] NLM/ NIHMS621073; NLM/ PMC4157573
  •  go-up   go-down


13. Payré B, de Medina P, Boubekeur N, Mhamdi L, Bertrand-Michel J, Tercé F, Fourquaux I, Goudounèche D, Record M, Poirot M, Silvente-Poirot S: Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism. Mol Cancer Ther; 2008 Dec;7(12):3707-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism.
  • The aim of the present study was to gain more insight into the control of breast cancer cell growth by AEBS ligands.
  • We report that PBPE and tamoxifen treatment induced differentiation in human breast adenocarcinoma cells MCF-7 as indicated by the arrest of cells in the G0-G1 phase of the cell cycle, the increase in the cell volume, the accumulation and secretion of lipids, and a milk fat globule protein found in milk.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Cholesterol / metabolism. Estrogen Receptor Modulators / pharmacology. Microsomes / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074846.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor Modulators; 0 / Ligands; 0 / Lipids; 0 / Milk Proteins; 094ZI81Y45 / Tamoxifen; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


1
Advertisement
4. Staff NP, Bosch EP, Engelstad J, Moynihan TJ, Spinner RJ, Dyck PJ: Metastatic lobular breast adenocarcinoma presenting as cauda equina syndrome. J Peripher Nerv Syst; 2010 Mar;15(1):75-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic lobular breast adenocarcinoma presenting as cauda equina syndrome.
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast Neoplasms / diagnosis. Meningeal Neoplasms / diagnosis. Peripheral Nervous System Neoplasms / diagnosis. Polyradiculopathy / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Spinal Nerves / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20433609.001).
  • [ISSN] 1529-8027
  • [Journal-full-title] Journal of the peripheral nervous system : JPNS
  • [ISO-abbreviation] J. Peripher. Nerv. Syst.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


15. Tommasi S, Dammann R, Zhang Z, Wang Y, Liu L, Tsark WM, Wilczynski SP, Li J, You M, Pfeifer GP: Tumor susceptibility of Rassf1a knockout mice. Cancer Res; 2005 Jan 1;65(1):92-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumors in Rassf1a-targeted mice included lung adenomas, lymphomas, and one breast adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / genetics. Animals. Base Sequence. Crosses, Genetic. DNA Primers. Genotype. Lung Neoplasms / genetics. Lymphoma / genetics. Mammary Neoplasms, Animal / genetics. Mice. Mice, Inbred C57BL. Mice, Knockout. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15665283.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA093643; United States / NCI NIH HHS / CA / CA88873
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RASSF1 protein, mouse; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


16. Fischer E, Kobold S, Kleber S, Kubuschok B, Braziulis E, Knuth A, Renner C, Wadle A: Cryptic epitopes induce high-titer humoral immune response in patients with cancer. J Immunol; 2010 Sep 1;185(5):3095-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In search of novel markers for diagnosis, prognosis, and therapy of cancer, screening of rcDNA expression libraries with patient's sera has been established as a valuable tool for identification of cancer-specific Ags.
  • In our study, we specifically analyzed humoral immune response toward such peptides in patients with pancreatic or breast cancer using yeast-displayed cDNA expression libraries derived from tumor tissue.
  • Due to the high prevalence of immune responses against some of the peptides, they may also be valuable markers for cancer diagnosis, prognosis, or therapy monitoring.
  • [MeSH-major] Adenocarcinoma / immunology. Antibodies, Neoplasm / biosynthesis. Antigens, Neoplasm / immunology. Breast Neoplasms / immunology. Epitopes / immunology. Pancreatic Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20660712.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Epitopes
  •  go-up   go-down


17. Huss WJ, Gray DR, Greenberg NM, Mohler JL, Smith GJ: Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Res; 2005 Aug 01;65(15):6640-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.
  • Putative prostate stem cells and prostate tumor stem cells in benign and malignant human prostate tissue, in primary human prostate xenografts, and in the transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model of prostate cancer, are defined by expression of breast cancer resistance protein (BCRP), a marker of pluripotent hematopoietic, muscle, and neural stem cells, and by an absence of androgen receptor (AR) protein.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NOVOBIOCIN .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061644.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA84296; United States / NCI NIH HHS / CA / P01 CA077739; United States / NCI NIH HHS / CA / CA77739; United States / NCI NIH HHS / CA / CA64851; United States / NIEHS NIH HHS / ES / ES07017; United States / NCI NIH HHS / CA / CA64865
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Androgens; 0 / Indoles; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Receptors, Androgen; 17EC19951N / Novobiocin; CW5S8OP3VO / tryptoquivaline
  •  go-up   go-down


18. Voloudakis GE, Baltatzis GE, Agnantis NJ, Arnogianaki N, Misitzis J, Voloudakis-Baltatzis I: Surface topography and ultrastructural changes of mucinous carcinoma breast cells. Ultrastruct Pathol; 2007 Jul-Aug;31(4):263-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surface topography and ultrastructural changes of mucinous carcinoma breast cells.
  • Mucinous carcinoma of the breast (MCB) is histologically classified into 2 groups:.
  • Pure MCB carries a better diagnosis than mixed MCB.
  • [MeSH-major] Adenocarcinoma, Mucinous / ultrastructure. Breast Neoplasms / ultrastructure

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786827.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Shervington LA, Smith N, Norman E, Ward T, Phillips R, Shervington A: To determine the cytotoxicity of chlorambucil and one of its nitro-derivatives, conjugated to prasterone and pregnenolone, towards eight human cancer cell-lines. Eur J Med Chem; 2009 Jul;44(7):2944-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A comparison between the esters and the controls, namely chlorambucil and 3-nitrochlorambucil would suggest that all four esters possess to varying degrees, specificity towards the breast adenocarcinoma cell line (MDA-mb468) than the other seven cells' lines tested.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19121874.001).
  • [ISSN] 1768-3254
  • [Journal-full-title] European journal of medicinal chemistry
  • [ISO-abbreviation] Eur J Med Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Esters; 0 / Nitro Compounds; 18D0SL7309 / Chlorambucil; 459AG36T1B / Dehydroepiandrosterone; 73R90F7MQ8 / Pregnenolone
  •  go-up   go-down


20. Murakami A, Kawachi K, Sasaki T, Ishikawa T, Nagashima Y, Nozawa A: Sebaceous carcinoma of the breast. Pathol Int; 2009 Mar;59(3):188-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sebaceous carcinoma of the breast.
  • Sebaceous carcinoma (SC) of the breast is a rare malignant tumor and only nine cases, including the present one, have been reported in the English-language literature.
  • This is the first case of an androgen receptor-positive mammary SC to be reported, and therefore contributes to the understanding of the clinicopathological features of SC of the breast.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Breast Neoplasms / pathology. Receptors, Androgen / metabolism. Sebaceous Gland Neoplasms / pathology


21. Mahadevan NR, Fernandez A, Rodvold JJ, Almanza G, Zanetti M: Prostate cancer cells undergoing ER stress in vitro and in vivo activate transcription of pro-inflammatory cytokines. J Inflamm Res; 2010;3:99-103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Here, we show that transgenic adenocarcinoma of the mouse prostate (TRAMP) C1 murine prostate cancer cells induced to undergo ER stress in vitro activate the transcription of interleukin 6 (IL-6), interleukin 23p19 (IL-23p19), and tumor necrosis factor α (TNF-α).

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22096360.001).
  • [ISSN] 1178-7031
  • [Journal-full-title] Journal of inflammation research
  • [ISO-abbreviation] J Inflamm Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3218737
  • [Keywords] NOTNLM ; inflammation / tumorigenesis / unfolded protein response
  •  go-up   go-down


22. Mylonas I, Mayr D, Walzel H, Shabani N, Dian D, Kuhn C, Kunze S, Jeschke U, Friese K: Mucin 1, Thomsen-Friedenreich expression and galectin-1 binding in endometrioid adenocarcinoma: an immunohistochemical analysis. Anticancer Res; 2007 Jul-Aug;27(4A):1975-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucin 1, Thomsen-Friedenreich expression and galectin-1 binding in endometrioid adenocarcinoma: an immunohistochemical analysis.
  • BACKGROUND AND AIM: Altered mucin 1 (MUC1) secretion patterns have been implicated in several cancerous conditions including gastric, colorectal and breast carcinomas.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649808.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / Galectin 1; 0 / Mucin-1; 3554-90-3 / Thomsen-Friedenreich antigen
  •  go-up   go-down


23. Azatian A, Yu H, Dai W, Schneiders FI, Botelho NK, Lord RV: Effectiveness of HSV-tk suicide gene therapy driven by the Grp78 stress-inducible promoter in esophagogastric junction and gastric adenocarcinomas. J Gastrointest Surg; 2009 Jun;13(6):1044-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The HSV-tk gene, controlled by either the Grp78 promoter or the LTR promoter, was transduced into the gastroesophageal junction adenocarcinoma cell line SK-GT-5 and the gastric adenocarcinoma cell line MKN-74.
  • CONCLUSION: HSV-tk xwith ganciclovir suicide gene therapy results in significant cell killing in gastroesophageal junction and gastric adenocarcinoma cells both in vitro and in vivo, but complete tumor elimination only occurred with the gastric adenocarcinoma cell tumors.
  • [MeSH-major] Adenocarcinoma / therapy. Genes, Transgenic, Suicide / genetics. Genetic Therapy / methods. Heat-Shock Proteins / genetics. Stomach Neoplasms / therapy. Thymidine Kinase / genetics

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2002 Nov;37 Suppl 14:87-91 [12572873.001]
  • [Cites] J Surg Res. 2000 Jun 15;91(2):111-7 [10839958.001]
  • [Cites] J Surg Res. 2007 Jun 1;140(1):50-4 [17418868.001]
  • [Cites] Breast Cancer Res Treat. 2000 Jun;61(3):249-60 [10966001.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3496-9 [17440054.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1330-4 [1847517.001]
  • [Cites] Science. 1992 Jun 12;256(5063):1550-2 [1317968.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):649-57 [8334620.001]
  • [Cites] Cancer Gene Ther. 2004 Apr;11(4):289-96 [14765131.001]
  • [Cites] Curr Gene Ther. 2005 Dec;5(6):535-57 [16457645.001]
  • [Cites] Breast Cancer Res Treat. 2000 Jan;59(1):81-90 [10752683.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3795-800 [14666679.001]
  • [Cites] Mol Ther. 2006 Apr;13(4):716-28 [16480930.001]
  • [Cites] Cancer Biother Radiopharm. 2007 Dec;22(6):755-61 [18158766.001]
  • [Cites] Mol Ther. 2007 Apr;15(4):834-40 [17327829.001]
  • [Cites] Curr Gene Ther. 2008 Jun;8(3):187-200 [18537593.001]
  • [Cites] Mol Cell Biol. 1987 Jan;7(1):379-87 [3031469.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11400-6 [8876147.001]
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5B):4157-60 [10628368.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2008 Feb;14(1):3-8 [18292732.001]
  • [Cites] Cancer Gene Ther. 2001 May;8(5):342-51 [11477454.001]
  • [Cites] Dig Surg. 2005;22(4):222-33 [16174979.001]
  • [Cites] Hum Gene Ther. 1999 Mar 1;10(4):679-88 [10094211.001]
  • [Cites] Cancer Biol Ther. 2004 Nov;3(11):1075-80 [15477756.001]
  • [Cites] Hum Gene Ther. 2004 Jun;15(6):553-61 [15212714.001]
  • [Cites] World J Gastroenterol. 2006 Jan 21;12(3):380-7 [16489636.001]
  • [Cites] Gene Ther. 2003 Feb;10(3):206-12 [12571627.001]
  • [Cites] Ann Surg. 2003 Dec;238(6):815-24; discussion 825-6 [14631218.001]
  • [Cites] Gene Ther. 1999 Nov;6(11):1876-83 [10602383.001]
  • [Cites] Cancer Lett. 2006 Apr 28;235(2):191-201 [16752439.001]
  • [Cites] Int J Cancer. 1995 Feb 20;64(1):37-46 [7665247.001]
  • [Cites] Ann Thorac Surg. 2008 May;85(5):1837-8 [18446981.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 19277794.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Heat-Shock Proteins; 0 / molecular chaperone GRP78; EC 2.7.1.21 / Thymidine Kinase; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


24. Liang Z, Zeng X, Gao J, Wu S, Wang P, Shi X, Zhang J, Liu T: Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer; 2008;8:363
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.
  • [MeSH-major] Adenocarcinoma / genetics. Aneuploidy. Antigens, Neoplasm / metabolism. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Receptor, Epidermal Growth Factor / metabolism. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Mar;156(3):839-47 [10702400.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):1162-7 [17487844.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8887-95 [11751413.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1415-25 [11821356.001]
  • [Cites] Mod Pathol. 2002 Feb;15(2):137-45 [11850542.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):833-7 [11948459.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2625-9 [11980659.001]
  • [Cites] Oncogene. 2002 Sep 12;21(41):6255-63 [12214266.001]
  • [Cites] Leukemia. 2003 Mar;17(3):532-40 [12646941.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):234-41 [12679307.001]
  • [Cites] Cancer. 2003 Aug 25;99(4):233-9 [12925985.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3798-807 [12953099.001]
  • [Cites] Int J Cancer. 2003 Dec 10;107(5):764-72 [14566826.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):136-43 [14734462.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):548-53 [14991576.001]
  • [Cites] Cancer Res. 1989 Apr 15;49(8):2087-90 [2564806.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):533-42 [8630962.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1265-73 [15712203.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Breast J. 2005 Nov-Dec;11(6):448-53 [16297090.001]
  • [Cites] Science. 2006 Jun 23;312(5781):1798-802 [16794079.001]
  • [Cites] Dig Dis Sci. 2006 Aug;51(8):1371-9 [16868827.001]
  • [Cites] Hum Pathol. 2006 Oct;37(10):1333-43 [16949920.001]
  • [Cites] Curr Cancer Drug Targets. 2006 Nov;6(7):579-602 [17100565.001]
  • [Cites] Lung Cancer. 2006 Dec;54(3):387-98 [17011067.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):118-45 [17159189.001]
  • [Cites] Cancer Treat Rev. 2007 Feb;33(1):64-77 [17113234.001]
  • [Cites] J Thorac Oncol. 2007 May;2(5):414-22 [17473657.001]
  • [Cites] World J Surg. 2007 Jul;31(7):1458-68 [17516110.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:53-77 [11264450.001]
  • (PMID = 19061514.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2613415
  •  go-up   go-down


25. Nakazato Y, Tanaka R, Seki E, Iijima M, Kojima M, Yoshizumi M, Kato M, Kimura H, Kozawa K, Goya T: Differential diagnosis of primary versus metastatic pulmonary adenocarcinomas using gene mutation analyses: a case report. J Thorac Oncol; 2008 Aug;3(8):931-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of primary versus metastatic pulmonary adenocarcinomas using gene mutation analyses: a case report.
  • A 61-year-old Japanese woman underwent a partial mastectomy for cancer of the right breast (pT1cN0M0, stage I).
  • The nodule of S9 was pathologically diagnosed to be poorly differentiated adenocarcinoma.
  • The same pattern of the distribution of the p53 mutation was observed in the DNA samples of the S9 nodule and the treated breast cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / pathology. Lung Neoplasms / secondary. Lymph Nodes / pathology. Mutation / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] DNA Mutational Analysis. Diagnosis, Differential. Female. Humans. Mastectomy, Radical. Middle Aged. Polymerase Chain Reaction. Thyroidectomy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670315.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


26. McLaren BK, Gobbi H, Schuyler PA, Olson SJ, Parl FF, Dupont WD, Page DL: Immunohistochemical expression of estrogen receptor in enlarged lobular units with columnar alteration in benign breast biopsies: a nested case-control study. Am J Surg Pathol; 2005 Jan;29(1):105-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of estrogen receptor in enlarged lobular units with columnar alteration in benign breast biopsies: a nested case-control study.
  • The prognostic and therapeutic implications of estrogen receptor (ER) status in breast cancer are well known.
  • Whether ER status plays a role in benign breast lesions and the progression to malignancy has not been proven.
  • Enlarged lobular units with columnar alteration (ELUCA), also known as unfolded lobular units, have been associated with mild elevations in subsequent breast cancer risk.
  • We examined the association of ERalpha expression in ELUCA with invasive breast cancer risk.
  • A nested case-control study was performed of women with ELUCA who had undergone benign breast surgery.
  • Eighty-two women who developed invasive breast cancer on follow-up were matched by age and year of biopsy with 166 women who did not develop invasive breast cancer.
  • Relative risks of breast cancer were estimated by odds ratios derived from conditional logistic regression analyses.
  • The relative risk of invasive breast cancer in women with ERalpha-negative ELUCA was 1.85 times that of women with ERalpha-positive lesions (95% confidence interval, 1.0-3.4, P=0.04).
  • These findings have implications for risk assessment in benign breast biopsies and are of particular interest given the controversy currently surrounding hormone replacement therapy.
  • [MeSH-major] Adenocarcinoma / metabolism. Breast / metabolism. Breast Neoplasms / metabolism. Carcinoma in Situ / metabolism. Precancerous Conditions / metabolism. Receptors, Estrogen / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613861.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen
  •  go-up   go-down


27. Blanco-Aparicio C, Pérez-Gallego L, Pequeño B, Leal JF, Renner O, Carnero A: Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer. Carcinogenesis; 2007 Mar;28(3):584-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer.
  • We have found that while carcinogen-treated wild-type mice show mostly mammary tumors of sarcomatous origin, AKT transgenic mice treated with DMBA developed mainly adenocarcinoma or adenosquamous tumors, all of them displaying activated AKT.
  • These data show that AKT activation cooperates with deregulation of the estrogen receptor in the DMBA-induced mammary tumorigenesis model and recapitulate two characteristics of some human breast tumors.
  • Thus, our model might provide a preclinical relevant model system to study the role of AKT and ERalpha in breast tumorigenesis and the response of mammary gland tumors to chemotherapeutics.
  • [MeSH-major] 9,10-Dimethyl-1,2-benzanthracene / toxicity. Breast Neoplasms / genetics. Carcinogens / toxicity. Mammary Neoplasms, Animal / genetics. Myristic Acid / metabolism. Proto-Oncogene Proteins c-akt / genetics


28. Izadi-Mood N, Samadi N, Sarmadi S, Eftekhar Z: Papillary serous carcinoma arising from adenomyosis presenting as intramural leiomyoma. Arch Iran Med; 2007 Apr;10(2):258-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenocarcinoma arising from adenomyosis uteri is rare.
  • The patient was a 61-year-old woman who received tamoxifen for treatment of her breast cancer over the past five years.
  • [MeSH-major] Carcinoma, Papillary / pathology. Endometriosis / pathology. Leiomyoma / diagnosis. Myometrium / pathology. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Atrophy. Breast Neoplasms / drug therapy. Female. Humans. Middle Aged. Tamoxifen / therapeutic use


29. Mohammad A, Makaju R: Retrospective histopathological analysis of various neoplasms of the female reproductive system (FRS) seen at the Kathmandu University Teaching Hospital, (KUTH) Dhulikhel, Nepal. Kathmandu Univ Med J (KUMJ); 2006 Jan-Mar;4(1):48-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Out of these, 1 (1.7%) was of the vagina (squamous cell carcinoma, papillary variant); 16 (26.7%) were of the cervix of the uterus (all squamous cell carcinoma in advanced stage); none were of the endometrium; 20 (33.3%) were of the body of the uterus/uterine muscle (all liomyomas); 16 (26.7%) were of the ovary, (11 benign, consisting of nine mature cystic tertoma, also known as dermoid cyst, one serous papillary cystdenoma and one mucinous cystadenoma; and, five malignant, consisting of two serous cystadenocarcinoma, two mucinous cystadenocarcinoma and one mixed mucinous and serous cystadenocarcinoma); and, 7 (11.6%) were of the breast (two benign, consisting of fibroadenoma and five malignant, all consisting of infiltrating ductal carcinoma in advanced stage).
  • All breast cancers seen were also in advanced stage.
  • [MeSH-minor] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal / pathology. Carcinoma, Squamous Cell / pathology. Cystadenocarcinoma / pathology. Cystadenoma / pathology. Female. Fibroadenoma / pathology. Humans. Leiomyoma / pathology. Nepal. Ovarian Neoplasms / pathology. Retrospective Studies. Uterine Cervical Neoplasms / pathology. Uterine Neoplasms / pathology. Vaginal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18603868.001).
  • [ISSN] 1812-2027
  • [Journal-full-title] Kathmandu University medical journal (KUMJ)
  • [ISO-abbreviation] Kathmandu Univ Med J (KUMJ)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


30. Minard ME, Ellis LM, Gallick GE: Tiam1 regulates cell adhesion, migration and apoptosis in colon tumor cells. Clin Exp Metastasis; 2006;23(5-6):301-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Guanine Nucleotide Exchange Factors / physiology. Neoplasm Proteins / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2004 Sep 15;18(18):2225-30 [15371335.001]
  • [Cites] J Biol Chem. 2000 Jan 21;275(3):1829-38 [10636882.001]
  • [Cites] Science. 1993 Apr 2;260(5104):85-8 [8465203.001]
  • [Cites] Science. 1997 Nov 21;278(5342):1464-6 [9367959.001]
  • [Cites] J Cell Biol. 1999 Nov 29;147(5):1009-22 [10579721.001]
  • [Cites] J Cell Biol. 1997 Apr 21;137(2):387-98 [9128250.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):41889-97 [11551917.001]
  • [Cites] Nat Cell Biol. 2002 Aug;4(8):621-5 [12134164.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1310-8 [15319235.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] Cancer Res. 1976 Dec;36(12):4562-9 [1000501.001]
  • [Cites] J Biol Chem. 1997 Nov 7;272(45):28447-54 [9353304.001]
  • [Cites] J Cell Biol. 1997 Nov 3;139(3):797-807 [9348295.001]
  • [Cites] Oncogene. 1995 Dec 7;11(11):2215-21 [8570171.001]
  • [Cites] World J Gastroenterol. 2005 Feb 7;11(5):705-7 [15655826.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2004 Aug;36(8):537-40 [15295645.001]
  • [Cites] Int J Oncol. 2006 Feb;28(2):411-20 [16391796.001]
  • [Cites] J Cell Biol. 2000 Jul 10;150(1):177-91 [10893266.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Nature. 1995 May 25;375(6529):338-40 [7753201.001]
  • [Cites] Differentiation. 2006 Jun;74(5):254-64 [16759291.001]
  • [Cites] J Cell Sci. 2004 Sep 15;117(Pt 20):4863-71 [15340013.001]
  • [Cites] Science. 1986 Oct 17;234(4774):364-8 [2876518.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(1):21-32 [14999151.001]
  • [Cites] Mol Cell Neurosci. 1997 Jan;9(1):1-12 [9204476.001]
  • [Cites] Cancer Biol Ther. 2005 Apr;4(4):365-70 [15846061.001]
  • [Cites] J Biol Chem. 2003 Sep 5;278(36):34339-46 [12810717.001]
  • [Cites] Nature. 2002 Jun 20;417(6891):867-71 [12075356.001]
  • [Cites] J Biol Chem. 2001 Jul 27;276(30):28443-50 [11328805.001]
  • [Cites] Oncogene. 1995 Apr 6;10(7):1371-6 [7731688.001]
  • [Cites] Cancer Res. 1988 Dec 1;48(23):6863-71 [2846163.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4385-90 [11274357.001]
  • [Cites] Cell. 1994 May 20;77(4):537-49 [7999144.001]
  • [Cites] Oncogene. 2001 Aug 16;20(36):4942-50 [11526479.001]
  • [Cites] Oncogene. 2002 Nov 7;21(51):7797-807 [12420216.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):740-6 [14644200.001]
  • [Cites] Methods Enzymol. 2006;407:269-81 [16757331.001]
  • [Cites] Eur J Cancer. 2000 Jun;36(10):1269-74 [10882865.001]
  • [Cites] J Biol Chem. 2006 Jan 6;281(1):543-8 [16249175.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):369-76 [11054665.001]
  • [Cites] Biochem J. 2000 Oct 1;351(Pt 1):173-82 [10998360.001]
  • [Cites] Oncol Rep. 2003 May-Jun;10(3):527-32 [12684618.001]
  • [Cites] Bioessays. 2001 Oct;23(10):912-23 [11598958.001]
  • [Cites] J Cell Biol. 2005 Dec 5;171(5):871-81 [16330714.001]
  • [Cites] Oncogene. 2005 Apr 7;24(15):2568-73 [15735692.001]
  • [Cites] FEBS Lett. 2003 Dec 18;555(3):556-60 [14675773.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] J Biol Chem. 1998 Jan 9;273(2):1052-7 [9422768.001]
  • (PMID = 17086355.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Guanine Nucleotide Exchange Factors; 0 / Neoplasm Proteins; 0 / RAC1 protein, human; 0 / RNA, Small Interfering; 0 / Recombinant Fusion Proteins; 0 / TIAM1 protein, human; EC 3.6.5.2 / rac1 GTP-Binding Protein
  •  go-up   go-down


31. Cruz-Monserrate Z, O'Connor KL: Integrin alpha 6 beta 4 promotes migration, invasion through Tiam1 upregulation, and subsequent Rac activation. Neoplasia; 2008 May;10(5):408-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lethality of pancreatic adenocarcinoma stems from an elevated incidence of tumor cell invasion and metastasis that are mediated by mechanisms not yet understood.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Adhesion. Chemotaxis. Hepatocyte Growth Factor / pharmacology. Humans. Neoplasm Invasiveness. RNA, Small Interfering / pharmacology. Tumor Cells, Cultured. Up-Regulation

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):32287-93 [15161909.001]
  • [Cites] Oncogene. 2004 Mar 25;23(13):2385-400 [14767473.001]
  • [Cites] Int J Cancer. 1975 May 15;15(5):741-7 [1140870.001]
  • [Cites] In Vitro. 1982 Jan;18(1):24-34 [7182348.001]
  • [Cites] J Biol Chem. 1989 Apr 15;264(11):6529-35 [2649503.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3568-73 [8012983.001]
  • [Cites] Cancer Res. 1995 Mar 1;55(5):1129-38 [7866999.001]
  • [Cites] Nature. 1995 May 25;375(6529):338-40 [7753201.001]
  • [Cites] J Cell Biol. 1999 Nov 29;147(5):1063-72 [10579725.001]
  • [Cites] Science. 1999 Nov 5;286(5442):1102-3 [10610524.001]
  • [Cites] Oncol Rep. 2000 Jan-Feb;7(1):13-6 [10601583.001]
  • [Cites] J Biol Chem. 2000 Apr 7;275(14):10604-10 [10744756.001]
  • [Cites] J Cell Biol. 2000 May 15;149(4):775-82 [10811819.001]
  • [Cites] EMBO J. 2000 Jun 1;19(11):2393-8 [10835338.001]
  • [Cites] Biochem J. 2000 Oct 1;351(Pt 1):173-82 [10998360.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):129-41 [11322832.001]
  • [Cites] Oncogene. 2001 Nov 1;20(50):7437-46 [11704875.001]
  • [Cites] Cell. 2001 Nov 30;107(5):643-54 [11733063.001]
  • [Cites] J Biol Chem. 2001 Dec 21;276(51):47895-900 [11606581.001]
  • [Cites] Nature. 2002 Jun 20;417(6891):867-71 [12075356.001]
  • [Cites] Cell. 2002 Sep 20;110(6):673-87 [12297042.001]
  • [Cites] Nature. 2003 Feb 6;421(6923):639-43 [12571598.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2649-57 [12750293.001]
  • [Cites] J Pathol. 2003 Sep;201(1):63-74 [12950018.001]
  • [Cites] J Cell Biol. 2003 Dec 22;163(6):1397-407 [14691145.001]
  • [Cites] Cell. 1994 May 20;77(4):537-49 [7999144.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(1):21-32 [14999151.001]
  • [Cites] Mol Biol Cell. 2007 Nov;18(11):4210-21 [17699601.001]
  • [Cites] J Biol Chem. 1995 Sep 29;270(39):22673-6 [7559386.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):959-63 [8640785.001]
  • [Cites] Science. 1997 Nov 21;278(5342):1464-6 [9367959.001]
  • [Cites] Nature. 1997 Dec 11;390(6660):632-6 [9403696.001]
  • [Cites] Cell. 1997 Dec 26;91(7):949-60 [9428518.001]
  • [Cites] J Invest Dermatol. 1999 Apr;112(4):411-8 [10201522.001]
  • [Cites] Cell Adhes Commun. 1999;7(1):1-11 [10228731.001]
  • [Cites] J Cell Biol. 1999 Sep 6;146(5):1147-60 [10477766.001]
  • [Cites] Genomics. 1999 Oct 1;61(1):66-73 [10512681.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):39-49 [15652748.001]
  • [Cites] J Histochem Cytochem. 2005 Jun;53(6):799-801 [15928331.001]
  • [Cites] Cancer Metastasis Rev. 2005 Sep;24(3):413-23 [16258729.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10674-9 [16322210.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1645-52 [17308105.001]
  • [Cites] Mod Pathol. 2007 Jun;20(6):656-67 [17415382.001]
  • [Cites] FASEB J. 2007 Sep;21(11):2776-86 [17428964.001]
  • [Cites] J Biol Chem. 2007 Oct 19;282(42):30643-57 [17702746.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26 [15459662.001]
  • (PMID = 18472958.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / F31 CA106201; United States / NCI NIH HHS / CA / F31 CA106201; United States / NCI NIH HHS / CA / R01 CA109136; United States / NCI NIH HHS / CA / R21 CA102125; United States / NCI NIH HHS / CA / R21 CA102125
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Guanine Nucleotide Exchange Factors; 0 / Integrin alpha6beta4; 0 / RAC1 protein, human; 0 / RNA, Small Interfering; 0 / TIAM1 protein, human; 67256-21-7 / Hepatocyte Growth Factor; EC 3.6.5.2 / rac1 GTP-Binding Protein
  • [Other-IDs] NLM/ PMC2373869
  •  go-up   go-down


32. Kamitani K, Ono M, Toyoshima S, Mitsuyama S, Anan K, Ikeda Y: Isoechoic axillary lymph node metastases of mucinous carcinoma of the breast: a case report. Breast Cancer; 2006;13(4):382-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isoechoic axillary lymph node metastases of mucinous carcinoma of the breast: a case report.
  • We report a case of isoechoic axillary lymph node metastasis of mucinous carcinoma (so-called pure mucinous carcinoma) of the breast.
  • A 47-year-old premenopausal woman was referred to our hospital with a 2 years history of mass and distortion of her left breast and with recent worsening of her symptoms.
  • Based on a preoperative diagnosis of mucinous carcinoma of the left breast with left axillary lymph nodes metastases, left mastectomy and left axillary nodal dissection were performed.
  • Although lymph node metastasis of mucinous carcinoma of the breast is rare, ultrasonographers should perform careful scanning when the primary breast mass is suspicious for mucinous carcinoma, because lymph node metastases of mucinous carcinoma can be more indistinct and difficult to detect than those of other types of breast cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Axilla / pathology. Breast Neoplasms / pathology. Lymphatic Metastasis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17146168.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


33. Moinpour CM, Vaught NL, Goldman B, Redman MW, Philip PA, Millwood B, Lippman SM, Seay TE, Flynn PJ, O'Reilly EM, Rowland KM, Wong RP, Benedetti J, Blanke CD: Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer. J Clin Oncol; 2010 Aug 01;28(22):3611-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / psychology. Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Pain / drug therapy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / psychology. Quality of Life

  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Qual Life Res. 1994 Oct;3(5):339-52 [7531054.001]
  • [Cites] N Engl J Med. 1994 Mar 3;330(9):592-6 [7508092.001]
  • [Cites] Pain. 1995 May;61(2):277-84 [7659438.001]
  • [Cites] Qual Life Res. 1996 Feb;5(1):65-72 [8901368.001]
  • [Cites] Qual Life Res. 1996 Oct;5(5):469-80 [8973126.001]
  • [Cites] Stat Med. 1997 Jan 15-Feb 15;16(1-3):239-57 [9004395.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3662-73 [9817289.001]
  • [Cites] Breast Cancer Res Treat. 1998 Sep;51(2):169-81 [9879778.001]
  • [Cites] Psychosomatics. 1999 Jul-Aug;40(4):309-13 [10402876.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1998-2004 [10430384.001]
  • [Cites] Biostatistics. 2005 Apr;6(2):241-58 [15772103.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2828-35 [16782921.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3946-52 [16921047.001]
  • [Cites] Support Care Cancer. 2006 Nov;14(11):1126-33 [16601947.001]
  • [Cites] Digestion. 2006;74(2):116-7 [17183191.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Jun;36(2):335-64, ix [17533083.001]
  • [Cites] J Pain Symptom Manage. 2007 Dec;34(6):628-38 [17703910.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3695-701 [18669454.001]
  • [Cites] J Clin Oncol. 2010 Aug 1;28(22):3605-10 [20606093.001]
  • [Cites] Psychooncology. 2000 Jul-Aug;9(4):340-54 [10960931.001]
  • [Cites] Psychooncology. 2001 Jan-Feb;10(1):19-28 [11180574.001]
  • [Cites] Pain. 2001 Nov;94(2):149-58 [11690728.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2229-39 [11980994.001]
  • [Cites] Br J Cancer. 2002 Jul 15;87(2):161-7 [12107836.001]
  • [Cites] Stat Med. 2003 Mar 15;22(5):795-809 [12587106.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3296-302 [12947065.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1430-8 [15084616.001]
  • [Cites] Cancer. 1982 Nov 1;50(9):1913-8 [7116316.001]
  • [Cites] Pain. 1983 Oct;17(2):197-210 [6646795.001]
  • [Cites] Cancer. 1987 Nov 15;60(10):2563-9 [2444328.001]
  • [Cites] Hosp J. 1990;6(1):1-13 [2379920.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):748-55 [7884435.001]
  • (PMID = 20606094.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / U10 CA077202; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / CA77651; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / U10 CA035195; United States / NCI NIH HHS / CA / CA35195; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / U10 CA077651; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / CA77202; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / CA25224; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / U10 CA025224; United States / NCI NIH HHS / CA / CA31946
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; PQX0D8J21J / Cetuximab
  • [Other-IDs] NLM/ PMC2917316
  •  go-up   go-down


34. Enomoto K, Sakurai K, Amano S, Shiono M: [A case of malignant lymphoma that seemed to be thyroid cancer lymph nodes recurrence]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2213-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathology diagnosis showed it to be of a papillary adenocarcinoma of thyroid recurrence.
  • The diagnosis was malignant lymphoma.


35. Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JM, Coffman K, Jackson D, Bruckheimer E, Muraoka-Cook RS, Chen J: The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest; 2008 Jan;118(1):64-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
  • Overexpression of the receptor tyrosine kinase EPH receptor A2 (EphA2) is commonly observed in aggressive breast cancer and correlates with a poor prognosis.
  • Biochemical analyses revealed that EphA2 formed a complex with ErbB2 in human and murine breast carcinoma cells, resulting in enhanced activation of Ras-MAPK signaling and RhoA GTPase.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2005 Nov 24;24(53):7859-68 [16103880.001]
  • [Cites] Neoplasia. 2006 Jan;8(1):18-30 [16533422.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7050-8 [16849550.001]
  • [Cites] J Invest Dermatol. 2006 Nov;126(11):2490-506 [16888633.001]
  • [Cites] Mol Cancer Res. 2006 Oct;4(10):769-78 [17050670.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70 [17077358.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10315-24 [17079451.001]
  • [Cites] Cancer. 2006 Nov 15;107(10):2425-35 [17041885.001]
  • [Cites] J Biol Chem. 2007 Jan 26;282(4):2683-94 [17135240.001]
  • [Cites] Mol Cancer Res. 2007 Mar;5(3):283-93 [17374733.001]
  • [Cites] Nat Rev Cancer. 2007 May;7(5):389-97 [17446858.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):357-61 [11920586.001]
  • [Cites] Cancer Gene Ther. 2004 Nov;11(11):757-66 [15359289.001]
  • [Cites] Curr Pharm Des. 2004;10(27):3431-42 [15544526.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9002-11 [15604265.001]
  • [Cites] Curr Cancer Drug Targets. 2005 May;5(3):149-57 [15892616.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jun;6(6):462-75 [15928710.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6910-8 [16061675.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6042-5 [10626787.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):1038-44 [10713687.001]
  • [Cites] Oncogene. 2000 Apr 20;19(17):2129-37 [10815804.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):3081-7 [10850460.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • [Cites] Oncogene. 2000 Dec 7;19(52):6043-52 [11146556.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2301-6 [11280802.001]
  • [Cites] J Biol Chem. 2001 Apr 27;276(17):13771-7 [11278471.001]
  • [Cites] Nat Cell Biol. 2001 May;3(5):527-30 [11331884.001]
  • [Cites] Nature. 2001 May 17;411(6835):355-65 [11357143.001]
  • [Cites] Mol Biol Cell. 2001 May;12(5):1445-55 [11359934.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):785-92 [11533657.001]
  • [Cites] Oncogene. 2001 Oct 4;20(45):6503-15 [11641774.001]
  • [Cites] Nat Cell Biol. 2001 Nov;3(11):950-7 [11715015.001]
  • [Cites] Oncogene. 2001 Nov 26;20(54):7908-16 [11753673.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(7):2204-19 [11884607.001]
  • [Cites] Science. 2002 Apr 19;296(5567):550-3 [11910072.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Oct;6(4):393-406 [12013529.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2840-7 [12019162.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Aug 9;296(1):214-20 [12147253.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7011-26 [12370823.001]
  • [Cites] Oncogene. 2002 Oct 31;21(50):7690-9 [12400011.001]
  • [Cites] N Engl J Med. 2002 Nov 14;347(20):1593-603 [12432047.001]
  • [Cites] Mol Cancer Res. 2002 Nov;1(1):79-87 [12496371.001]
  • [Cites] Surgery. 2003 Feb;133(2):219-21 [12605184.001]
  • [Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]
  • [Cites] J Cell Sci. 2003 Jul 15;116(Pt 14):2823-32 [12808016.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3425-9 [12810680.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):2113-26 [14578209.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(23):8691-703 [14612410.001]
  • [Cites] Cancer Biol Ther. 2003 Sep-Oct;2(5):572-8 [14614330.001]
  • [Cites] Neoplasia. 2003 Sep-Oct;5(5):445-56 [14670182.001]
  • [Cites] Mol Cancer Res. 2003 Dec;1(14):1070-6 [14707290.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):910-9 [14871820.001]
  • [Cites] Oncogene. 2004 Feb 19;23(7):1448-56 [14973554.001]
  • [Cites] J Cell Sci. 2004 Apr 15;117(Pt 10):2037-49 [15054110.001]
  • [Cites] J Biol Chem. 2004 Jun 4;279(23):24505-13 [15044465.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Aug 6;320(4):1096-102 [15249202.001]
  • [Cites] Nat Med. 2004 Aug;10(8):789-99 [15286780.001]
  • [Cites] Angiogenesis. 2004;7(1):17-28 [15302992.001]
  • [Cites] Breast Cancer Res Treat. 2004 Sep;87(1):87-95 [15377854.001]
  • [Cites] Dev Cell. 2004 Oct;7(4):465-80 [15469835.001]
  • [Cites] Mol Cell Biol. 1992 Mar;12(3):954-61 [1312220.001]
  • [Cites] Endocr Rev. 1992 Feb;13(1):3-17 [1313356.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10578-82 [1359541.001]
  • [Cites] Breast Cancer Res Treat. 1994 Jan;29(1):73-83 [8018964.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):3140-8 [7606735.001]
  • [Cites] Science. 1995 Sep 1;269(5228):1270-2 [7652575.001]
  • [Cites] Lab Anim Sci. 1999 Apr;49(2):179-88 [10331548.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):111-8 [16098464.001]
  • [Cites] FASEB J. 2005 Nov;19(13):1884-6 [16166198.001]
  • (PMID = 18079969.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA95004; United States / NCI NIH HHS / CA / R01 CA095004; United States / NCI NIH HHS / CA / R01 CA114301; United States / NCI NIH HHS / CA / CA1179151-02; United States / NCI NIH HHS / CA / CA114301
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Erbb2 protein, mouse; EC 2.7.10.1 / Receptor, EphA2; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.6.5.2 / RhoA protein, mouse; EC 3.6.5.2 / rho GTP-Binding Proteins
  • [Other-IDs] NLM/ PMC2129239
  •  go-up   go-down


36. Showalter SL, Charles S, Belin J, Cozzitorto J, Einstein P, Richards NG, Sauter PK, Kennedy EP, Witkiewicz A, Brody JR, Yeo CJ: Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future. Expert Opin Drug Deliv; 2010 Mar;7(3):273-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent preclinical data have demonstrated that pancreatic adenocarcinoma (PDA) cells with defects in the Fanconi anemia/BRCA2 pathway are hypersensitive to interstrand crosslinking agents.
  • Patient A developed PDA in the context of a known BRCA2 frameshift mutation (2157delG), suspected because of her personal and multigenerational family history of breast cancer.
  • Patient A continues to be disease free 32 months after her diagnosis and treatment.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20201734.001).
  • [ISSN] 1744-7593
  • [Journal-full-title] Expert opinion on drug delivery
  • [ISO-abbreviation] Expert Opin Drug Deliv
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


37. Vijay H, Navil VK, Vaibhav J, Chopra A, Goel A, Sood R: Body aches, tender bones and rapid loss of weight: a case report. Cases J; 2009;2(1):37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sometimes these may be confused with infective or inflammatory conditions, particularly in young individuals, and degenerative conditions of the spine and hip in elderly, which may delay the diagnosis and treatment leading to poor outcomes.
  • A bone marrow biopsy showed infiltration by tumor cells suggestive of metastatic adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2477-90 [16339096.001]
  • [Cites] Skeletal Radiol. 1998 Nov;27(11):641-5 [9867183.001]
  • [Cites] Bull Cancer. 1988;75(9):845-57 [3207894.001]
  • [Cites] J Bone Joint Surg Am. 1993 Sep;75(9):1276-81 [8408149.001]
  • [Cites] Bone. 1991;12 Suppl 1:S7 [1954048.001]
  • [Cites] Acta Radiol. 1996 Jul;37(4):512-6 [8688232.001]
  • (PMID = 19134213.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2637836
  •  go-up   go-down


38. Misiek M, Williams J, Schmich K, Hüttel W, Merfort I, Salomon CE, Aldrich CC, Hoffmeister D: Structure and cytotoxicity of arnamial and related fungal sesquiterpene aryl esters. J Nat Prod; 2009 Oct;72(10):1888-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Arnamial showed cytotoxicity against Jurkat T cells, MCF-7 breast adenocarcinoma, CCRF-CEM lymphoblastic leukemia, and HCT-116 colorectal carcinoma cells at IC50 = 3.9, 15.4, 8.9, and 10.7 microM, respectively, and the related aryl ester melledonal C showed cytotoxic activity against CCRF-CEM cells (IC50 = 14.75 microM).

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19795841.001).
  • [ISSN] 1520-6025
  • [Journal-full-title] Journal of natural products
  • [ISO-abbreviation] J. Nat. Prod.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Esters; 0 / Sesquiterpenes; 0 / arnamial
  •  go-up   go-down


39. Oshima T, Cao X, Grande F, Yamada R, Garofalo A, Louie S, Neamati N: Combination effects of SC144 and cytotoxic anticancer agents. Anticancer Drugs; 2009 Jun;20(5):312-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Administration, Oral. Animals. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Cell Line, Tumor / drug effects. Cell Survival. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / pathology. Drug Screening Assays, Antitumor. Drug Synergism. Female. Humans. Inhibitory Concentration 50. Injections, Intraperitoneal. Mice. Mice, Nude. Organoplatinum Compounds / pharmacology. Paclitaxel / pharmacology. Xenograft Model Antitumor Assays

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19322070.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytotoxins; 0 / Organoplatinum Compounds; 0 / Pyrazines; 0 / Quinoxalines; 0 / SC 144; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


40. Queiroz MJ, Calhelha RC, Vale-Silva LA, Pinto E, São-José Nascimento M: Novel 6-[(hetero)arylamino]thieno[3,2-b]pyridines: synthesis and antitumoral activities. Eur J Med Chem; 2010 Dec;45(12):5732-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The antitumoral activity of the di(hetero)arylamines obtained was evaluated against three representative human tumor cell lines, namely breast adenocarcinoma (MCF-7), melanoma (A375-C5), and non-small cell lung cancer (NCI-H460) and some structure-activity relationships were established within each series.

  • Hazardous Substances Data Bank. PALLADIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20934235.001).
  • [ISSN] 1768-3254
  • [Journal-full-title] European journal of medicinal chemistry
  • [ISO-abbreviation] Eur J Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Pyridines; 0 / thienopyridine; 5TWQ1V240M / Palladium
  •  go-up   go-down


46. Tjalma WA: Horner's syndrome: an ominous sign in breast cancer. Eur J Obstet Gynecol Reprod Biol; 2006 Jun 1;126(2):270-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Horner's syndrome: an ominous sign in breast cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast Neoplasms / diagnosis. Horner Syndrome. Liver Neoplasms / diagnosis. Thoracic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Mammography. Neoplasm Metastasis. Tomography, X-Ray Computed


47. Masciullo V, Mainenti S, Lorusso D, Margariti PA, Scambia G: Lethal Clostridium difficile Colitis Associated with Paclitaxel and Carboplatin Chemotherapy in Ovarian Carcinoma: Case Report and Review of the Literature. Obstet Gynecol Int; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 75-year-old woman with serous adenocarcinoma of the ovary developed lethal pancolitis caused by C. difficile after five cycles of paclitaxel- and carboplatin-based chemotherapy.
  • We describe the second case reported of a patient developing a severe C. difficile colitis following chemotherapy without any recent antibiotic use and review the data of the literature, emphasizing the need to a prompt diagnosis and management that can significantly decrease the morbidity and life-threatening complications associated with this infection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] West J Med. 1989 Dec;151(6):644-8 [2694622.001]
  • [Cites] Clin Infect Dis. 2007 Aug 1;45(3):302-7 [17599306.001]
  • [Cites] Kans Med. 1986 May;87(5):133, 146 [3712916.001]
  • [Cites] CA Cancer J Clin. 1995 Jan-Feb;45(1):8-30 [7528632.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2643-55 [7595719.001]
  • [Cites] Infect Control Hosp Epidemiol. 1994 Jun;15(6):371-81 [7632199.001]
  • [Cites] N Engl J Med. 1995 Apr 13;332(15):1004-14 [7885406.001]
  • [Cites] N Engl J Med. 1994 Jan 27;330(4):257-62 [8043060.001]
  • [Cites] Gynecol Oncol. 1993 Jul;50(1):45-8 [8349164.001]
  • [Cites] Arch Intern Med. 1992 Aug;152(8):1715-7 [1497405.001]
  • [Cites] J Natl Cancer Inst. 1991 Feb 20;83(4):288-91 [1671606.001]
  • [Cites] J Natl Cancer Inst. 1990 Aug 1;82(15):1247-59 [1973737.001]
  • [Cites] Gynecol Oncol. 1996 Jun;61(3):369-72 [8641617.001]
  • [Cites] Gynecol Oncol. 1997 Nov;67(2):137-40 [9367696.001]
  • [Cites] Gynecol Oncol. 1998 Oct;71(1):104-7 [9784328.001]
  • [Cites] Lancet. 2000 Jan 22;355(9200):281-3 [10675076.001]
  • [Cites] J Clin Gastroenterol. 2001 Aug;33(2):159-60 [11468447.001]
  • [Cites] Clin Infect Dis. 2001 Sep 15;33(6):786-91 [11512083.001]
  • [Cites] Breast. 2001 Aug;10(4):346-7 [14965607.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1508-13 [15378497.001]
  • [Cites] AJR Am J Roentgenol. 2006 May;186(5):1393-400 [16632736.001]
  • [Cites] Ann Surg. 2007 Feb;245(2):267-72 [17245181.001]
  • [Cites] Br J Cancer. 1986 Mar;53(3):355-60 [3516192.001]
  • (PMID = 20706661.001).
  • [ISSN] 1687-9597
  • [Journal-full-title] Obstetrics and gynecology international
  • [ISO-abbreviation] Obstet Gynecol Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2913858
  •  go-up   go-down


48. García-Tuñón I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M: OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative). Cancer Invest; 2008 Apr-May;26(3):222-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative).
  • Immunoexpressions of LIF, OSM, LIFRbeta and OSMRbeta were studied in benign breast lesion, in situ and infiltrating tumors by Western blot and immunohistochemistry.
  • In conclusions, development of breast tumor increases the expression of OSM, LIF, OSMRbeta, LIFRbeta and gp130, and this expression may be associated with the malignancy.
  • IL-6 family exert their action through transducer receptor gp130, and gp130 expression increase with malignance, it might be a crucial point in the development of infiltrative adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Carcinoma in Situ / metabolism. Leukemia Inhibitory Factor / biosynthesis. Oncostatin M / biosynthesis. Receptors, OSM-LIF / biosynthesis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317962.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / LIF protein, human; 0 / Leukemia Inhibitory Factor; 0 / OSM protein, human; 0 / Receptors, OSM-LIF; 106956-32-5 / Oncostatin M; 133483-10-0 / Cytokine Receptor gp130
  •  go-up   go-down


49. Damast S, Ho AY, Montgomery L, Fornier MN, Ishill N, Elkin E, Beal K, McCormick B: Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era. Int J Radiat Oncol Biol Phys; 2010 Jul 15;77(4):1105-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era.
  • PURPOSE: To assess locoregional outcomes of inflammatory breast cancer (IBC) patients who received standard fractionation radiation with daily skin bolus and taxanes as part of combined-modality therapy (CMT).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Inflammatory breast cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19879068.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; 6804DJ8Z9U / Capecitabine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil
  •  go-up   go-down


50. Schuller HM, Al-Wadei HA, Majidi M: GABA B receptor is a novel drug target for pancreatic cancer. Cancer; 2008 Feb 15;112(4):767-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer death.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Cancer 2008. (c) 2007 American Cancer Society.
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5272-7 [15958573.001]
  • [Cites] J Cell Biochem. 2005 Jul 1;95(4):649-56 [15849724.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Oct;131(10):639-48 [16091975.001]
  • [Cites] Pancreas. 2005 Nov;31(4):301-16 [16258363.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):369-75 [16428474.001]
  • [Cites] J Clin Anesth. 2005 Dec;17(8):586-91 [16427527.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1370-80 [16206275.001]
  • [Cites] Invest New Drugs. 2005 Dec;23(6):583-90 [16034525.001]
  • [Cites] Auton Neurosci. 2006 Jan 30;124(1-2):1-8 [16338174.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2744-9 [16381019.001]
  • [Cites] Biochem Pharmacol. 2006 May 14;71(10):1397-421 [16563357.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Jun;58(3):231-41 [16725343.001]
  • [Cites] Pancreas. 2006 Jul;33(1):53-62 [16804413.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1547-52 [16671086.001]
  • [Cites] Trends Plant Sci. 2006 Sep;11(9):424-7 [16890474.001]
  • [Cites] J Agric Food Chem. 2006 Sep 6;54(18):6765-75 [16939338.001]
  • [Cites] Plant Physiol. 2006 Dec;142(4):1350-2 [17151138.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):93-8 [17182741.001]
  • [Cites] Toxicol Sci. 2007 Mar;96(1):21-9 [17003101.001]
  • [Cites] Cancer Treat Rev. 2000 Feb;26(1):29-52 [10660490.001]
  • [Cites] Am J Pathol. 2000 Nov;157(5):1623-31 [11073822.001]
  • [Cites] J Cancer Res Clin Oncol. 2000 Nov;126(11):624-30 [11079726.001]
  • [Cites] Carcinogenesis. 2001 Mar;22(3):473-9 [11238189.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2866-9 [11306460.001]
  • [Cites] Oncogene. 2001 Mar 26;20(13):1532-9 [11313899.001]
  • [Cites] Int J Oncol. 2002 Jul;21(1):153-7 [12063562.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):455-63 [12189387.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6467-9 [12438237.001]
  • [Cites] Eur J Pharmacol. 2003 Feb 28;463(1-3):235-72 [12600714.001]
  • [Cites] Breast Cancer Res Treat. 2003 Jul;80(1):63-70 [12889599.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3327-32 [15161686.001]
  • [Cites] J Biol Chem. 2004 Sep 17;279(38):40209-19 [15210690.001]
  • [Cites] Arch Int Pharmacodyn Ther. 1969 Jun;179(2):343-51 [5367308.001]
  • [Cites] Eur J Cell Biol. 1990 Feb;51(1):76-84 [2328739.001]
  • [Cites] Scand J Clin Lab Invest Suppl. 1990;201:25-43 [1978755.001]
  • [Cites] Eur J Clin Invest. 1992 May;22(5):301-6 [1592082.001]
  • [Cites] Can J Anaesth. 1993 May;40(5 Pt 1):435-9 [8390330.001]
  • [Cites] J Pharmacol Exp Ther. 1996 Jun;277(3):1209-14 [8667180.001]
  • [Cites] Gastroenterology. 1998 Sep;115(3):714-21 [9721169.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2223-8 [10232612.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4510-5 [10493497.001]
  • [Cites] J Nutr. 2004 Dec;134(12 Suppl):3445S-3452S [15570052.001]
  • [Cites] Biofactors. 2004;22(1-4):165-7 [15630275.001]
  • [Cites] Cesk Fysiol. 2004;53(3):117-24 [15702867.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jun;29(5):733-7 [15939520.001]
  • (PMID = 18098271.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA042829; United States / NCI NIH HHS / CA / R01 CA42829
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic beta-Agonists; 0 / GABA Agents; 0 / GABA Agonists; 0 / Receptors, GABA; 56-12-2 / gamma-Aminobutyric Acid; E0399OZS9N / Cyclic AMP; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; G34N38R2N1 / Bromodeoxyuridine; H789N3FKE8 / Baclofen; L628TT009W / Isoproterenol
  • [Other-IDs] NLM/ NIHMS381601; NLM/ PMC3375598
  •  go-up   go-down


51. Gallagher MF, Flavin RJ, Elbaruni SA, McInerney JK, Smyth PC, Salley YM, Vencken SF, O'Toole SA, Laios A, Lee MY, Denning K, Li J, Aherne ST, Lao KQ, Martin CM, Sheils OM, O'Leary JJ: Regulation of microRNA biosynthesis and expression in 2102Ep embryonal carcinoma stem cells is mirrored in ovarian serous adenocarcinoma patients. J Ovarian Res; 2009;2:19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of microRNA biosynthesis and expression in 2102Ep embryonal carcinoma stem cells is mirrored in ovarian serous adenocarcinoma patients.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS Pathog. 2009 Apr;5(4):e1000389 [19381257.001]
  • [Cites] J Gastroenterol Hepatol. 2009 Apr;24(4):652-7 [19175831.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3356-63 [19351832.001]
  • [Cites] J Biol Chem. 2009 Apr 24;284(17):11326-35 [19251704.001]
  • [Cites] PLoS One. 2009;4(3):e4998 [19308264.001]
  • [Cites] Nucleic Acids Res. 2009 Apr;37(5):1672-81 [19153141.001]
  • [Cites] Oncology. 2009;76(3):162-9 [19209007.001]
  • [Cites] J Biol Chem. 2009 Feb 27;284(9):5731-41 [19073608.001]
  • [Cites] Cancer Gene Ther. 2009 Mar;16(3):206-16 [18949015.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1177-83 [19228723.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Free Radic Biol Med. 2009 Jan 15;46(2):282-8 [19022373.001]
  • [Cites] J Ovarian Res. 2008;1:8 [19025622.001]
  • [Cites] N Engl J Med. 2008 Dec 18;359(25):2641-50 [19092150.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10307-14 [19074899.001]
  • [Cites] Eur J Cancer Prev. 2009 Feb;18(1):50-5 [19077565.001]
  • [Cites] Gynecol Oncol. 2008 Dec;111(3):478-86 [18823650.001]
  • [Cites] Nature. 2008 Dec 4;456(7222):593-8 [19052619.001]
  • [Cites] RNA. 2008 Nov;14(11):2348-60 [18812439.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1124-8 [18806776.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Nov 7;376(1):86-90 [18765229.001]
  • [Cites] BMC Med. 2008;6:15 [18577221.001]
  • [Cites] BMC Med. 2008;6:14 [18577219.001]
  • [Cites] PLoS One. 2008;3(6):e2436 [18560586.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 13;105(19):7004-9 [18458333.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2588-92 [18451220.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2690-5 [18451233.001]
  • [Cites] J Biol Chem. 2008 May 9;283(19):13205-15 [18319255.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3903-8 [18308936.001]
  • [Cites] Oncogene. 2008 Mar 13;27(12):1788-93 [17891175.001]
  • [Cites] Cell. 2008 Mar 7;132(5):875-86 [18329372.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1362-8 [18316599.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cell. 2008 Feb 22;132(4):563-6 [18295575.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1608-13 [18227514.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D154-8 [17991681.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):26-33 [18172293.001]
  • [Cites] RNA. 2008 Jan;14(1):35-42 [18025253.001]
  • [Cites] Mol Cancer. 2007;6:60 [17894887.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8699-707 [17875710.001]
  • [Cites] Oncogene. 2007 Jun 28;26(30):4442-52 [17237814.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):976-83 [17283129.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D149-55 [17108354.001]
  • [Cites] Nat Genet. 2006 Sep;38(9):1060-5 [16878133.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5078-83 [16549775.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Apr 28;343(1):85-9 [16529715.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Biochem Soc Trans. 2005 Dec;33(Pt 6):1526-30 [16246161.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 1964 Oct;24:1544-51 [14234000.001]
  • [Cites] Lab Invest. 1984 Feb;50(2):147-62 [6694356.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] J Cell Sci. 2004 Jul 15;117(Pt 16):3539-45 [15226377.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Proc Nutr Soc. 2000 Feb;59(1):127-34 [10828182.001]
  • [Cites] BMC Cancer. 2009;9:194 [19538740.001]
  • [Cites] Breast Cancer Res. 2009;11(3):R27 [19432961.001]
  • [Cites] Exp Cell Res. 2009 Sep 10;315(15):2529-38 [19501585.001]
  • [Cites] Hepatology. 2009 Jul;50(1):113-21 [19441017.001]
  • [Cites] J Gastroenterol. 2009;44(6):556-61 [19363643.001]
  • [Cites] Pancreatology. 2009;9(3):293-301 [19407485.001]
  • [Cites] Leuk Lymphoma. 2009 Mar;50(3):506-9 [19347736.001]
  • (PMID = 20015364.001).
  • [ISSN] 1757-2215
  • [Journal-full-title] Journal of ovarian research
  • [ISO-abbreviation] J Ovarian Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2805659
  •  go-up   go-down


52. Dutsch-Wicherek M, Popiela TJ, Klimek M, Rudnicka-Sosin L, Wicherek L, Oudinet JP, Skladzien J, Tomaszewska R: Metallothionein stroma reaction in tumor adjacent healthy tissue in head and neck squamous cell carcinoma and breast adenocarcinoma. Neuro Endocrinol Lett; 2005 Oct;26(5):567-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metallothionein stroma reaction in tumor adjacent healthy tissue in head and neck squamous cell carcinoma and breast adenocarcinoma.
  • The aim of our study was to evaluate the MT expression in head and neck squamous cells carcinoma and breast adenocarcinoma and their histologically healthy adjacent tissue.
  • MATERIALS AND METHODS: We have sampled 29 tissue samples in total derived from head and neck cancers and 29 samples of their clear surgical margins, 33 breast adenocarcinomas and 33 clear surgical margins.
  • RESULTS: MT expression was revealed in 85,7% of head and neck cancers and 94% of breast adenocarcinomas.
  • MT expression was statistically significantly higher in tumor adjacent tissue than in cancer tissue in cases with the presence of lymph node metastases in both, breast adenocarcinoma and head and neck squamous cell carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Carcinoma, Squamous Cell / metabolism. Head and Neck Neoplasms / metabolism. Metallothionein / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16264399.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] 9038-94-2 / Metallothionein
  •  go-up   go-down


53. Baselga J, Zambetti M, Llombart-Cussac A, Manikhas G, Kubista E, Steger GG, Makhson A, Tjulandin S, Ludwig H, Verrill M, Ciruelos E, Egyhazi S, Xu LA, Zerba KE, Lee H, Clark E, Galbraith S: Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol; 2009 Feb 1;27(4):526-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer.
  • PURPOSE: This phase II study evaluated the efficacy and safety of ixabepilone as neoadjuvant therapy for invasive breast cancer not amenable to breast conservation surgery.
  • PATIENTS AND METHODS: Patients with invasive breast cancer >or= 3 cm were eligible.
  • The overall complete pathologic response (pCR) rate was 18% in breast and 29% in estrogen receptor (ER) -negative patients.
  • ER gene expression (ER1) was inversely related to pCR in breast and had a positive predictive value (PPV) of 37% and negative predictive value (NPV) of 92%.
  • Neoadjuvant ixabepilone demonstrated promising activity and a manageable safety profile in patients with invasive breast tumors.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Epothilones / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Ixabepilone .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19075286.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Epothilones; 0 / RNA, Messenger; 0 / Receptors, Estrogen; K27005NP0A / ixabepilone
  •  go-up   go-down


54. Mejía W, Castro C, Umaña A, de Castro C, Riveros T, Sánchez-Gómez M: [Insulin-like growth factor receptor I signaling in a breast cancer cell line]. Biomedica; 2010 Oct-Dec;30(4):551-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Insulin-like growth factor receptor I signaling in a breast cancer cell line].
  • [Transliterated title] Señalización asociada al receptor del factor de crecimiento similar a la insulina de tipo I en una línea celular colombiana de carcinoma mamario.
  • INTRODUCTION: In vitro studies strongly suggest that proliferation, migration and cell survival of breast cancer cell lines are significantly affected by activation of the IGF type 1 receptor (IGF-IR).
  • OBJECTIVE: The phosphorylation by IGF-I of IGF-IR and the intracellular signaling molecules Akt (PI-3K pathway) and Erk1/2 (MAPK pathway) was characterized in a human breast cancer cell lines.
  • MATERIALS AND METHODS: The study compared a standard breast adenocarcinoma line (MCF-7) cell line with a line (CSC 1595) derived from an infiltrating ductal breast cancer in a Colombian patient.
  • Since the IGF-IR is the major activator of this pathway it may play an important role in ductal infiltrating breast cancer tumor growth and metastases.
  • [MeSH-major] Breast Neoplasms / physiopathology. Cell Line, Tumor. Receptor, IGF Type 1 / metabolism. Signal Transduction / physiology


55. Shigemitsu A, Furukawa N, Koike N, Kobayashi H: Endometrial cancer diagnosed by the presence of bone metastasis and treated with zoledronic Acid: a case report and review of the literature. Case Rep Oncol; 2010 Sep;3(3):471-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological sections of an endometrial biopsy showed endometrioid adenocarcinoma.
  • A moderately differentiated endometrioid adenocarcinoma was expressed in the corpus.
  • Histopathological examination of the bone biopsy also revealed adenocarcinoma.
  • The final diagnosis was stage IVB endometrial cancer with bone and lung metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 2002 Jul;21(3):281-4 [12068176.001]
  • [Cites] Breast. 2003 Aug;12 Suppl 2:S30-6 [14659141.001]
  • [Cites] Cancer. 1950 Jan;3(1):74-85 [15405683.001]
  • [Cites] Gynecol Oncol. 1992 May;45(2):142-6 [1592280.001]
  • [Cites] Clin Exp Metastasis. 2007;24(2):87-92 [17364220.001]
  • [Cites] J Foot Ankle Surg. 2005 Nov-Dec;44(6):462-5 [16257676.001]
  • [Cites] BJU Int. 2009 Mar;103(5):620-4 [18990143.001]
  • [Cites] J Gynecol Oncol. 2009 Jun;20(2):67-71 [19590716.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2779-81 [8194019.001]
  • [Cites] Gynecol Oncol. 1990 Nov;39(2):108-14 [2227582.001]
  • [Cites] Ann Surg. 1940 Jul;112(1):138-49 [17857618.001]
  • (PMID = 21611145.001).
  • [ISSN] 1662-6575
  • [Journal-full-title] Case reports in oncology
  • [ISO-abbreviation] Case Rep Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3100269
  • [Keywords] NOTNLM ; Bisphosphonates / Bone metastasis / Endometrial cancer
  •  go-up   go-down


56. Yoshida S, Takahashi H: Expression of extracellular matrix molecules in brain metastasis. J Surg Oncol; 2009 Jul 1;100(1):65-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tumors from 40 patients with brain metastasis (30 lung cancer, 10 breast cancer) were studied to investigate the expression-patterns of EGFR, MT1-MMP, MMP7, and CD44 using the immunostaining and RT -PCR analysis.
  • RESULTS: EGFR immunostaining was detected in 92% (23/25) and 70% (7/10) of brain metastasis from lung adenocarcinoma and breast cancer, respectively.
  • MT1-MMP immunostaining was also detected in 80% (20/25) and 50% (5/10) of brain metastasis from lung adenocarcinoma and breast cancer, respectively.
  • EGFR mRNA was detected in 83.3% (25/30) and 70% (7/10) of brain metastasis from lung cancer and breast cancer, respectively.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19402080.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / CD44 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.80 / MMP14 protein, human; EC 3.4.24.80 / Matrix Metalloproteinase 14
  •  go-up   go-down


57. Hummel JL, Safroneeva E, Mossman KL: The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma. Mol Ther; 2005 Dec;12(6):1101-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma.
  • Using an immunocompetent murine model of breast adenocarcinoma we demonstrate that the ICP0 mutant KM100 completely eradicates tumors in approximately 80% of treated animals and significantly increases survival.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Genetic Therapy / methods. Herpesvirus 1, Human / metabolism. Immediate-Early Proteins / genetics. Interferons / genetics. Ubiquitin-Protein Ligases / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140040.001).
  • [ISSN] 1525-0016
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immediate-Early Proteins; 9008-11-1 / Interferons; EC 6.3.2.19 / Ubiquitin-Protein Ligases; EC 6.3.2.19 / Vmw110 protein, Human herpesvirus 1
  •  go-up   go-down


58. Kim JY, Choi SJ, Oh JM, Park T, Choy JH: Anticancer drug-inorganic nanohybrid and its cellular interaction. J Nanosci Nanotechnol; 2007 Nov;7(11):3700-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We also examined the anticancer efficacy of MTX-LDH in human breast adenocarcinoma MCF-7 cells.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Inorganic Chemicals / chemistry. Methotrexate / administration & dosage. Methotrexate / pharmacokinetics. Nanoparticles / chemistry

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18047040.001).
  • [ISSN] 1533-4880
  • [Journal-full-title] Journal of nanoscience and nanotechnology
  • [ISO-abbreviation] J Nanosci Nanotechnol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / Hydroxides; 0 / Inorganic Chemicals; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


59. Lachkar S, Bota S, Nouvet G, Thiberville L: [Acute encephalopathy after infusion of paclitaxel]. Rev Mal Respir; 2006 Feb;23(1 Pt 1):73-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Encéphalopathie aiguë après injection de paclitaxel.
  • INTRODUCTION: Paclitaxel is an anti-neoplastic agent commonly used in the treatment of primary bronchial carcinoma and tumours of the breast and ovary.
  • CASE REPORT: We report a case of acute encephalopathy, occurring eight hours after infusion of Paclitaxel, in a patient treated for adenocarcinoma of the lung.
  • The diagnosis of encephalopathy secondary to Paclitaxel injection was reached after exclusion of other possible aetiologies.

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604029.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 12
  •  go-up   go-down


60. Yu C, Friday BB, Lai JP, Yang L, Sarkaria J, Kay NE, Carter CA, Roberts LR, Kaufmann SH, Adjei AA: Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther; 2006 Sep;5(9):2378-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple tumor cell lines of varying histiotypes, including A549 (lung adenocarcinoma), 786-O (renal cell carcinoma), HeLa (cervical carcinoma), MDA-MB-231 (breast), K562 (chronic myelogenous leukemia), Jurkat (acute T-cell leukemia), MEC-2 (B-chronic lymphocytic leukemia), and U251 and D37 (glioma), as well as cells derived from primary human glioma tumors that are likely a more clinically relevant model were treated with sorafenib or bortezomib alone or in combination.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16985072.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Boronic Acids; 0 / Phenylurea Compounds; 0 / Protease Inhibitors; 0 / Proteasome Inhibitors; 0 / Pyrazines; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 69G8BD63PP / Bortezomib; 9ZOQ3TZI87 / sorafenib; EC 2.7.11.1 / Oncogene Protein v-akt; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


61. Seo SI, Song SY, Kang MR, Kim MS, Oh JE, Kim YR, Lee JY, Yoo NJ, Lee SH: Immunohistochemical analysis of NF-kappaB signaling proteins IKKepsilon, p50/p105, p52/p100 and RelA in prostate cancers. APMIS; 2009 Aug;117(8):623-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A recent study revealed that IkappaB kinase epsilon (IKKepsilon), an activator of NF-kappaB, was overexpressed in breast cancers and acted as an oncogene.
  • We analyzed the expression of IKKepsilon, p50/105, p52/p100 and RelA in 107 prostate adenocarcinoma tissues by immunohistochemistry using a tissue microarray (TMA) method.
  • [MeSH-major] Adenocarcinoma / pathology. I-kappa B Kinase / biosynthesis. NF-kappa B p50 Subunit / biosynthesis. NF-kappa B p52 Subunit / biosynthesis. Prostatic Neoplasms / pathology. Transcription Factor RelA / biosynthesis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19664134.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / NF-kappa B p50 Subunit; 0 / NF-kappa B p52 Subunit; 0 / Transcription Factor RelA; EC 2.7.11.10 / I-kappa B Kinase
  •  go-up   go-down


62. Peralta EA, Murphy LL, Minnis J, Louis S, Dunnington GL: American Ginseng inhibits induced COX-2 and NFKB activation in breast cancer cells. J Surg Res; 2009 Dec;157(2):261-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] American Ginseng inhibits induced COX-2 and NFKB activation in breast cancer cells.
  • BACKGROUND: Epidemiologic evidence suggests reduced breast cancer mortality in users of American Ginseng (AG) (Panax quinquefolium).
  • We hypothesized that AG extract decreases proliferation of human breast cancer cells via an anti-inflammatory effect applicable to the prevention of breast and other cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Cell Proliferation / drug effects. Cyclooxygenase 2 / metabolism. NF-kappa B / metabolism. Panax. Plant Extracts / pharmacology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19815237.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / NF-kappa B; 0 / Plant Extracts; 136601-57-5 / Cyclin D1; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


63. Lin YL, Sengupta S, Gurdziel K, Bell GW, Jacks T, Flores ER: p63 and p73 transcriptionally regulate genes involved in DNA repair. PLoS Genet; 2009 Oct;5(10):e1000680
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Animals. BRCA2 Protein / metabolism. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Cell Survival / genetics. Cells, Cultured. Chromatin Immunoprecipitation. Cluster Analysis. DNA Repair Enzymes / metabolism. Immunohistochemistry. Mice. Promoter Regions, Genetic. Rad51 Recombinase / metabolism. Radiation, Ionizing. Tumor Protein p73. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Mar 2;404(6773):99-103 [10716451.001]
  • [Cites] Genes Dev. 2008 Oct 1;22(19):2677-91 [18805989.001]
  • [Cites] Nat Rev Mol Cell Biol. 2000 Dec;1(3):199-207 [11252895.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Nucleic Acids Res. 2001 Jun 15;29(12):2549-57 [11410663.001]
  • [Cites] Cell Growth Differ. 2001 Jul;12(7):337-49 [11457731.001]
  • [Cites] Nature. 2002 Apr 4;416(6880):560-4 [11932750.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3493-7 [12067993.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8467-72 [12077306.001]
  • [Cites] J Exp Med. 2002 Sep 16;196(6):765-80 [12235210.001]
  • [Cites] Oncogene. 2002 Dec 16;21(58):8994-9007 [12483515.001]
  • [Cites] Development. 2003 Apr;130(7):1327-37 [12588849.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(16):5540-55 [12897129.001]
  • [Cites] Mol Cell Biol. 2004 Jan;24(2):487-501 [14701724.001]
  • [Cites] Mol Cancer Res. 2003 Dec;1(14):1048-57 [14707288.001]
  • [Cites] Cell Death Differ. 2004 Mar;11(3):357-60 [14685155.001]
  • [Cites] DNA Repair (Amst). 2004 Aug-Sep;3(8-9):835-43 [15279768.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Science. 1995 Oct 20;270(5235):467-70 [7569999.001]
  • [Cites] Nature. 1997 Sep 11;389(6647):191-4 [9296498.001]
  • [Cites] Mol Cell. 1998 Sep;2(3):305-16 [9774969.001]
  • [Cites] Bioinformatics. 1998;14(9):755-63 [9918945.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):708-13 [10227293.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):714-8 [10227294.001]
  • [Cites] Cell. 2005 Feb 25;120(4):497-512 [15734682.001]
  • [Cites] Cell. 2005 Mar 25;120(6):843-56 [15797384.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):363-73 [15837625.001]
  • [Cites] Cell Cycle. 2005 Jul;4(7):865-7 [15917654.001]
  • [Cites] Cell. 2006 Jan 13;124(1):207-19 [16413492.001]
  • [Cites] J Biol Chem. 2006 Feb 3;281(5):2533-42 [16319057.001]
  • [Cites] EMBO Rep. 2006 Feb;7(2):219-24 [16322760.001]
  • [Cites] EMBO J. 2006 Apr 19;25(8):1764-74 [16601701.001]
  • [Cites] Mol Cell. 2006 Nov 17;24(4):593-602 [17188034.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):300-4 [17264676.001]
  • [Cites] Oncogene. 2007 Mar 8;26(11):1626-35 [16964288.001]
  • [Cites] BMC Bioinformatics. 2007;8 Suppl 1:S20 [17430565.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2471-8 [17438107.001]
  • [Cites] Oncogene. 2007 Nov 15;26(52):7363-70 [17563751.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • (PMID = 19816568.001).
  • [ISSN] 1553-7404
  • [Journal-full-title] PLoS genetics
  • [ISO-abbreviation] PLoS Genet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA-16672; United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BRCA2 Protein; 0 / BRCA2 protein, mouse; 0 / DNA-Binding Proteins; 0 / Mre11a protein, mouse; 0 / Nuclear Proteins; 0 / Phosphoproteins; 0 / Trans-Activators; 0 / Trp63 protein, mouse; 0 / Trp73 protein, mouse; 0 / Tumor Protein p73; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; EC 2.7.7.- / Rad51 Recombinase; EC 2.7.7.- / Rad51 protein, mouse; EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ PMC2752189
  •  go-up   go-down


64. Gimi B, Mori N, Ackerstaff E, Frost EE, Bulte JW, Bhujwalla ZM: Noninvasive MRI of endothelial cell response to human breast cancer cells. Neoplasia; 2006 Mar;8(3):207-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninvasive MRI of endothelial cell response to human breast cancer cells.
  • HUVECs were labeled with a superparamagnetic iron oxide T(2) contrast agent and cocultured with MDA-MB-231 breast cancer cells in the presence of an extracellular matrix (ECM) gel.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Ferumoxides .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5866-73 [14522911.001]
  • [Cites] J Clin Invest. 2000 Jan;105(1):71-7 [10619863.001]
  • [Cites] Am J Pathol. 2004 Apr;164(4):1141-2 [15039202.001]
  • [Cites] Int J Dev Biol. 2004;48(5-6):583-98 [15349833.001]
  • [Cites] J Natl Cancer Inst. 1974 Sep;53(3):661-74 [4412247.001]
  • [Cites] J Cell Biol. 1988 Oct;107(4):1589-98 [3049626.001]
  • [Cites] Ann N Y Acad Sci. 1990;588:61-72 [2192650.001]
  • [Cites] Cell. 1991 Jan 25;64(2):327-36 [1703045.001]
  • [Cites] In Vitro Cell Dev Biol. 1991 Apr;27A(4):327-36 [1856158.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):843-5 [1279431.001]
  • [Cites] Br J Radiol. 1993 Mar;66(783):181-96 [7682469.001]
  • [Cites] Science. 1994 Apr 22;264(5158):569-71 [7512751.001]
  • [Cites] J Biol Chem. 1994 Oct 28;269(43):26988-95 [7929439.001]
  • [Cites] J Biol Chem. 1995 Jun 2;270(22):13333-40 [7768934.001]
  • [Cites] Nature. 1995 Jul 6;376(6535):62-6 [7596435.001]
  • [Cites] J Biol Chem. 1995 Aug 25;270(34):19761-6 [7544346.001]
  • [Cites] FEBS Lett. 1995 Aug 21;370(3):203-8 [7656977.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4575-80 [7553632.001]
  • [Cites] Science. 1995 Dec 1;270(5241):1500-2 [7491498.001]
  • [Cites] Cancer Res. 1995 Dec 15;55(24):6161-5 [8521408.001]
  • [Cites] Nature. 1996 Apr 4;380(6573):435-9 [8602241.001]
  • [Cites] Nature. 1996 Apr 4;380(6573):439-42 [8602242.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Cancer Metastasis Rev. 1995 Dec;14(4):263-77 [8821090.001]
  • [Cites] Science. 1997 Feb 14;275(5302):964-7 [9020076.001]
  • [Cites] J Biol Chem. 1998 Nov 13;273(46):30336-43 [9804796.001]
  • [Cites] J Cell Physiol. 1999 Mar;178(3):359-70 [9989782.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):375-84 [10027396.001]
  • [Cites] J Biol Chem. 1999 Jun 4;274(23):16349-54 [10347193.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3410-2; author reply 3412-3 [15525839.001]
  • [Cites] NMR Biomed. 2004 Nov;17(7):484-99 [15526347.001]
  • [Cites] NMR Biomed. 2004 Nov;17(7):513-7 [15526348.001]
  • [Cites] Blood. 2005 Jan 1;105(1):420-5 [15331444.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Nov 2;264(3):781-8 [10544009.001]
  • [Cites] Development. 1998 May;125(9):1591-8 [9521897.001]
  • [Cites] Cell Mol Life Sci. 2000 Jan 20;57(1):41-64 [10949580.001]
  • [Cites] Circ Res. 2001 Feb 2;88(2):167-74 [11157668.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1757-65 [11337373.001]
  • [Cites] Angiogenesis. 2001;4(2):113-21 [11806243.001]
  • [Cites] Acad Radiol. 2002 Aug;9 Suppl 2:S484-7 [12188316.001]
  • [Cites] Nat Med. 2002 Dec;8(12):1369-75 [12415261.001]
  • [Cites] J Cell Sci. 2003 Mar 15;116(Pt 6):1013-22 [12584245.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1138-43 [12615733.001]
  • [Cites] Circulation. 2003 May 13;107(18):2290-3 [12732608.001]
  • [Cites] Radiology. 2003 Aug;228(2):480-7 [12819345.001]
  • [Cites] Stem Cells. 1997;15(3):180-9 [9170209.001]
  • [Cites] J Mol Cell Cardiol. 1997 May;29(5):1321-30 [9201618.001]
  • [Cites] Am J Pathol. 2004 Apr;164(4):1131-9 [15039201.001]
  • (PMID = 16611414.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 2R01 CA82337; United States / NCI NIH HHS / CA / 1P50 CA 103175; United States / NINDS NIH HHS / NS / 1R01 NS045062; United States / NCI NIH HHS / CA / R01 CA082337; United States / NCI NIH HHS / CA / P50 CA103175; United States / NINDS NIH HHS / NS / R01 NS045062
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenic Proteins; 0 / Contrast Media; 0 / Gels; 0 / Growth Substances; 0 / Magnetite Nanoparticles; 0 / Neoplasm Proteins; 0 / Oxides; 25104-18-1 / Polylysine; E1UOL152H7 / Iron; G6N3J05W84 / ferumoxides; K3R6ZDH4DU / Dextrans; XM0M87F357 / Ferrosoferric Oxide
  • [Other-IDs] NLM/ PMC1578524
  •  go-up   go-down


65. Sakin V, Eskiocak U, Kars MD, Iseri OD, Gunduz U: hTERT gene expression levels and telomerase activity in drug resistant MCF-7 cells. Exp Oncol; 2008 Sep;30(3):202-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, the activity of telomerase reverse transcriptase (hTERT) and its gene expression levels were investigated in paclitaxel, docetaxel, vincristine and doxorubicin resistant human MCF-7 breast adenocarcinoma cells.
  • [MeSH-major] Breast Neoplasms / genetics. Cell Proliferation / drug effects. Drug Resistance, Neoplasm. Gene Expression Regulation, Enzymologic / physiology. Telomerase / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18806742.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Taxoids; 15H5577CQD / docetaxel; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


66. Seewaldt VL, Scott V: Images in clinical medicine. Rapid progression of basal-type breast cancer. N Engl J Med; 2007 Mar 29;356(13):e12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Images in clinical medicine. Rapid progression of basal-type breast cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17392297.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Tse GM, Tan PH, Chaiwun B, Putti TC, Lui PC, Tsang AK, Wong FC, Lo AW: p63 is useful in the diagnosis of mammary metaplastic carcinomas. Pathology; 2006 Feb;38(1):16-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 is useful in the diagnosis of mammary metaplastic carcinomas.
  • AIMS: p63 has been recently reported to be expressed in sarcomatoid/metaplastic carcinoma of the breast, in addition to its role as a myoepithelial marker.
  • For metaplastic carcinoma with epithelial component only, p63 was only expressed in the squamous cell component, but not the adenocarcinoma component.
  • CONCLUSIONS: Using p63 for diagnosis of metaplastic carcinoma gives a sensitivity of 65%, a specificity of 96%, a positive predictive value of 96%, and a negative predictive value of 66% and an accuracy of 78%.
  • p63 may be used as an adjunct marker in the diagnosis of metaplastic carcinoma.
  • [MeSH-major] Breast Neoplasms / chemistry. Breast Neoplasms / pathology. DNA-Binding Proteins / analysis. Trans-Activators / analysis. Tumor Suppressor Proteins / analysis
  • [MeSH-minor] Adult. Aged. Anion Exchange Protein 1, Erythrocyte / analysis. Antiporters / analysis. Biomarkers / analysis. Biomarkers, Tumor / analysis. Carcinoma, Adenosquamous / chemistry. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / chemistry. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Female. Humans. Immunohistochemistry. Keratins / analysis. Middle Aged. Sarcoma / chemistry. Sarcoma / diagnosis. Sarcoma / pathology. Sensitivity and Specificity. Transcription Factors. Vimentin / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484002.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anion Exchange Protein 1, Erythrocyte; 0 / Antiporters; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / CAM 5.2 antigen; 0 / DNA-Binding Proteins; 0 / SLC4A3 protein, human; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


68. Schlienger JL, Luca F, Vinzio S, Pradignac A: [Obesity and cancer]. Rev Med Interne; 2009 Sep;30(9):776-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some systematic review and meta-analyses assessed the strength of associations between body mass index and common cancers such as breast, endometrial, colon and adenocarcinoma of oesophagus.

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19524333.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers; 67763-96-6 / Insulin-Like Growth Factor I
  • [Number-of-references] 53
  •  go-up   go-down


69. Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, Yamamoto M, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H: Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol; 2008 Apr;38(4):250-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.
  • OBJECTIVE: Using integrated 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT), the clinical significance of 18F-FDG uptake was evaluated in patients with primary breast cancer.
  • METHODS: Clinicopathological correlation with the level of maximum standardized uptake values (SUV) 60 min obtained from preoperative 18F-FDG PET/CT were examined in 152 patients with primary breast cancer.
  • Multivariate analyses showed tumor invasive size, nuclear grade and estrogen receptor negativity were significantly correlated with SUV in primary breast cancer (P < 0.0001,< 0.0001, and < 0.012, respectively), and nuclear grade was significantly correlated with SUV in tumors of invasive size 2 cm or less (P < 0.0001).
  • CONCLUSIONS: High uptake of 18F-FDG would be predictive of poor prognosis in patients with primary breast cancer, and aggressive features of cancer cells in patients with early breast cancer.
  • 18F-FDG PET/CT could be a useful tool to pre-therapeutically predict biological characteristics and baseline risk of breast cancer.
  • [MeSH-major] Breast Neoplasms / metabolism. Fluorodeoxyglucose F18 / metabolism. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adult. Aged. Aged, 80 and over. Analysis of Variance. Biomarkers, Tumor / analysis. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Lobular / metabolism. Contrast Media. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Prognosis. Radiopharmaceuticals / metabolism. Receptor, ErbB-2 / analysis. Receptors, Estrogen. Receptors, Progesterone / analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18407934.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Contrast Media; 0 / Radiopharmaceuticals; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0Z5B2CJX4D / Fluorodeoxyglucose F18; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


70. Marzocchini R, Malentacchi F, Biagini M, Cirelli D, Luceri C, Caderni G, Raugei G: The expression of low molecular weight protein tyrosine phosphatase is up-regulated in 1,2-dimethylhydrazine-induced colon tumours in rats. Int J Cancer; 2008 Apr 1;122(7):1675-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies have assessed the role of low molecular weight protein tyrosine phosphatase (LMW-PTP) in cell transformation and tumour onset and progression, observing a significant increase in the expression of LMW-PTP mRNA and protein in human breast, colon, bladder and kidney tumour samples.
  • [MeSH-major] Adenocarcinoma / enzymology. Colonic Neoplasms / enzymology. Protein Tyrosine Phosphatases / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 1,2-DIMETHYLHYDRAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18058797.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; EC 3.1.3.48 / Protein Tyrosine Phosphatases; IX068S9745 / 1,2-Dimethylhydrazine
  •  go-up   go-down


71. O'Rourke JP, Ness SA: Alternative RNA splicing produces multiple forms of c-Myb with unique transcriptional activities. Mol Cell Biol; 2008 Mar;28(6):2091-101
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternative RNA splicing produces multiple forms of c-Myb with unique transcriptional activities.
  • The c-Myb transcription factor regulates the proliferation and differentiation of hematopoietic cells, and activated alleles of c-myb induce leukemias and lymphomas in animals.
  • Relatively minor changes in the structure of c-Myb protein change the genes that it regulates and can unleash its latent transforming activities.
  • Here, quantitative assays were used to analyze the alternative splicing of human c-myb transcripts.
  • We identified an array of variant transcripts, expressed in highly regulated, lineage-specific patterns, that were formed through the use of alternate exons 8A, 9A, 9B, 10A, 13A, and 14A.
  • Expression levels of the different splice variant transcripts were regulated independently of one another during human hematopoietic cell differentiation, and the alternative splicing of c-myb mRNAs was increased in primary leukemia samples.
  • The alternatively spliced c-myb transcripts were associated with polysomes and encoded a series of c-Myb proteins with identical DNA binding domains but unique C-terminal domains.
  • In several types of assays, the variant c-Myb proteins exhibited quantitative and qualitative differences in transcriptional activities and specificities.
  • The results suggest that the human c-myb gene encodes a family of related proteins with different transcriptional activities.
  • Enhanced alternative splicing may be a mechanism for unmasking the transforming activity of c-myb in human leukemias.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell. 1998 Jan;1(2):203-11 [9659917.001]
  • [Cites] Blood. 1997 Sep 1;90(5):1828-39 [9292515.001]
  • [Cites] Oncogene. 1999 May 13;18(19):3039-46 [10378699.001]
  • [Cites] J Biol Chem. 1999 Oct 1;274(40):28067-70 [10497154.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7647-54 [15520162.001]
  • [Cites] Blood. 2005 May 15;105(10):3855-61 [15687240.001]
  • [Cites] Stem Cells. 2005 Sep;23(8):1154-69 [15955831.001]
  • [Cites] Mol Cell. 2005 Dec 22;20(6):881-90 [16364913.001]
  • [Cites] Oncogene. 2006 Feb 2;25(5):795-805 [16205643.001]
  • [Cites] J Cell Sci. 2006 Jul 1;119(Pt 13):2635-41 [16787944.001]
  • [Cites] RNA. 2007 Mar;13(3):414-21 [17237355.001]
  • [Cites] Nat Struct Mol Biol. 2007 Mar;14(3):185-93 [17310252.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2373-9 [17095623.001]
  • [Cites] Nat Genet. 2007 May;39(5):593-5 [17435759.001]
  • [Cites] Nat Protoc. 2007;2(5):1236-47 [17546019.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1251-61 [17452517.001]
  • [Cites] Blood Cells Mol Dis. 2001 Mar-Apr;27(2):459-63 [11259168.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Oncogene. 2003 Jan 16;22(2):308-13 [12527900.001]
  • [Cites] Mol Cell Biol. 2003 Sep;23(18):6631-45 [12944488.001]
  • [Cites] Blood Cells Mol Dis. 2003 Sep-Oct;31(2):192-200 [12972026.001]
  • [Cites] J Biol Chem. 2003 Oct 31;278(44):42750-60 [12917399.001]
  • [Cites] Science. 2003 Dec 19;302(5653):2141-4 [14684825.001]
  • [Cites] Nat Immunol. 2004 Jul;5(7):721-9 [15195090.001]
  • [Cites] BMC Genomics. 2004 May 31;5(1):33 [15169551.001]
  • [Cites] J Biol Chem. 2004 Jul 9;279(28):29519-27 [15105423.001]
  • [Cites] Oncogene. 1989 Dec;4(12):1419-23 [2687764.001]
  • [Cites] Cell. 1989 Dec 22;59(6):1115-25 [2688896.001]
  • [Cites] Mol Cell Biol. 1990 Jun;10(6):2715-22 [2188096.001]
  • [Cites] Oncogene. 1990 Aug;5(8):1117-24 [2202948.001]
  • [Cites] Cell. 1990 Dec 21;63(6):1289-97 [2261644.001]
  • [Cites] Cell. 1991 May 17;65(4):677-89 [1709592.001]
  • [Cites] J Virol. 1992 Oct;66(10):6035-44 [1527851.001]
  • [Cites] Genes Dev. 1993 May;7(5):749-59 [7684005.001]
  • [Cites] Oncogene. 1993 Jul;8(7):1839-47 [8510928.001]
  • [Cites] Oncogene. 1994 Nov;9(11):3363-5 [7936662.001]
  • [Cites] Curr Top Microbiol Immunol. 1996;211:191-9 [8585950.001]
  • [Cites] Genes Dev. 1996 Aug 1;10(15):1858-69 [8756344.001]
  • [Cites] Oncogene. 1996 Nov 21;13(10):2205-12 [8950988.001]
  • [Cites] Biochim Biophys Acta. 1996 Dec 9;1288(3):F123-39 [9011176.001]
  • [Cites] Nature. 1997 Apr 17;386(6626):713-7 [9109487.001]
  • [Cites] J Virol. 1998 Aug;72(8):6813-21 [9658130.001]
  • (PMID = 18195038.001).
  • [ISSN] 1098-5549
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA118100; United States / NCI NIH HHS / CA / CA105257; United States / NCI NIH HHS / CA / R01 CA105257; United States / NCI NIH HHS / CA / R01 CA058443; United States / NIDDK NIH HHS / DK / P30 DK056465; United States / NIDDK NIH HHS / DK / DK56465; United States / NCI NIH HHS / CA / CA058443
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Protein Isoforms; 0 / Proto-Oncogene Proteins c-myb; 0 / Recombinant Fusion Proteins
  • [Other-IDs] NLM/ PMC2268396
  •  go-up   go-down


72. Jung MY, Kim SH, Cho D, Kim TS: Analysis of the expression profiles of cytokines and cytokine-related genes during the progression of breast cancer growth in mice. Oncol Rep; 2009 Nov;22(5):1141-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the expression profiles of cytokines and cytokine-related genes during the progression of breast cancer growth in mice.
  • Cytokines are a protein family of regulatory factors derived from tumors and their environmental components that contribute to the growth, invasion and metastasis of breast cancer.
  • In this study, we used an oligoDNA microarray to assess the kinetic expression profile of cytokine genes in tumor tissues and lymph nodes during the progression of tumor growth in mice that had been subcutaneously challenged with breast adenocarcinoma SB5b cells.
  • [MeSH-major] Adenocarcinoma / genetics. Cytokines / genetics. Gene Expression Profiling. Immunologic Factors / metabolism. Mammary Neoplasms, Experimental / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787232.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chemokines; 0 / Cytokines; 0 / Immunologic Factors; 0 / RNA, Messenger
  •  go-up   go-down


73. Tang H, Dong X, Day RS, Hassan MM, Li D: Antioxidant genes, diabetes and dietary antioxidants in association with risk of pancreatic cancer. Carcinogenesis; 2010 Apr;31(4):607-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To test the hypothesis that polymorphic variants of antioxidant genes modify the risk of pancreatic cancer, we examined seven single-nucleotide polymorphisms (SNPs) of genes coding for superoxide dismutase (SOD) 2, glutathione S-transferase alpha 4 (GSTA4), catalase and glutathione peroxidase in 575 patients with pancreatic adenocarcinoma and 648 healthy controls in a case-control study.

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Diabetes Complications.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin C.
  • MedlinePlus Health Information. consumer health - Vitamin E.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diabetes. 1999 Jan;48(1):1-9 [9892215.001]
  • [Cites] Cell Biochem Biophys. 2005;43(2):289-330 [16049352.001]
  • [Cites] Int J Obes (Lond). 2006 Mar;30(3):400-18 [16302012.001]
  • [Cites] Cardiovasc Hematol Disord Drug Targets. 2006 Mar;6(1):1-19 [16724932.001]
  • [Cites] Cancer. 2007 Mar 1;109(5):840-8 [17265526.001]
  • [Cites] Vitam Horm. 2007;76:309-27 [17628179.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1581-6 [17646272.001]
  • [Cites] Am J Gastroenterol. 2007 Dec;102(12):2696-707 [17764494.001]
  • [Cites] Cancer. 2008 Mar 1;112(5):1037-42 [18205184.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Mar;6(3):275-82 [18328435.001]
  • [Cites] Br J Nutr. 2008 Sep;100(3):633-41 [18279554.001]
  • [Cites] Diabetes Res Clin Pract. 2008 Sep;81(3):381-5 [18653258.001]
  • [Cites] Neuro Oncol. 2008 Oct;10(5):709-15 [18682580.001]
  • [Cites] Zhonghua Yu Fang Yi Xue Za Zhi. 2008 Jul;42(7):511-4 [19035188.001]
  • [Cites] Metabolism. 2009 Feb;58(2):254-62 [19154960.001]
  • [Cites] Cancer Genet Cytogenet. 2009 Feb;189(1):1-4 [19167605.001]
  • [Cites] Mol Carcinog. 2009 Mar;48(3):253-9 [18767114.001]
  • [Cites] Eur J Cancer. 2009 Nov;45(16):2874-81 [19467856.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 20;94(4):297-306 [11854392.001]
  • [Cites] Pancreas. 2003 Jan;26(1):23-7 [12499913.001]
  • [Cites] J Biochem Mol Toxicol. 2003;17(1):24-38 [12616644.001]
  • [Cites] Pharmacogenetics. 2003 Mar;13(3):145-57 [12618592.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1297-303 [12649190.001]
  • [Cites] Mol Cancer Ther. 2003 Apr;2(4):361-9 [12700280.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4594-601 [12907637.001]
  • [Cites] Carcinogenesis. 2004 Jun;25(6):973-8 [14729580.001]
  • [Cites] J Urol. 2004 Aug;172(2):728-32 [15247771.001]
  • [Cites] Am J Epidemiol. 1985 Jul;122(1):51-65 [4014201.001]
  • [Cites] Environ Health Perspect. 1985 Dec;64:111-26 [3007083.001]
  • [Cites] Ann N Y Acad Sci. 1993 May 28;686:12-27; discussion 27-8 [8512242.001]
  • [Cites] Lipids. 1996 Mar;31 Suppl:S87-90 [8729100.001]
  • [Cites] Biochem J. 1998 Feb 15;330 ( Pt 1):175-9 [9461507.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):602-6 [9973207.001]
  • [Cites] Breast Cancer Res. 2004;6(6):R647-55 [15535847.001]
  • [Cites] Cell Biochem Funct. 2005 Jan-Feb;23(1):73-6 [15386537.001]
  • [Cites] Free Radic Res. 2004 Nov;38(11):1223-33 [15621700.001]
  • [Cites] Int J Cancer. 2005 May 1;114(5):817-23 [15609315.001]
  • [Cites] J Gastroenterol. 2005 Mar;40(3):297-301 [15830290.001]
  • [Cites] Pharmacogenet Genomics. 2005 May;15(5):311-9 [15864132.001]
  • [Cites] Methods Enzymol. 2005;401:379-407 [16399399.001]
  • (PMID = 20097730.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098380; United States / NIEHS NIH HHS / ES / P30 ES07784; United States / NCI NIH HHS / CA / R01 CA98380
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 1406-18-4 / Vitamin E; EC 1.15.1.1 / Superoxide Dismutase; EC 1.15.1.1 / superoxide dismutase 2; EC 2.5.1.18 / Glutathione Transferase; EC 4.4.1.20 / leukotriene-C4 synthase; PQ6CK8PD0R / Ascorbic Acid
  • [Other-IDs] NLM/ PMC2847085
  •  go-up   go-down


74. Khalbuss WE, Ambaye A, Goodison S, Loya A, Masood S: Papillary carcinoma of the breast in a male patient with a treated prostatic carcinoma diagnosed by fine-needle aspiration biopsy: a case report and review of the literature. Diagn Cytopathol; 2006 Mar;34(3):214-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary carcinoma of the breast in a male patient with a treated prostatic carcinoma diagnosed by fine-needle aspiration biopsy: a case report and review of the literature.
  • Papillary carcinoma of the male breast is very rare.
  • In this case report, we describe the cytologic, histologic, immunohistochemical, and radiological findings of a papillary carcinoma of male breast.
  • A 67-yr-old man, who had a previous history of prostatic adenocarcinoma, presented with a retroareolar painless mass.
  • There was no known history of breast cancer in his family.
  • A diagnosis of papillary lesion favoring papillary carcinoma was rendered.
  • FNAB is a useful technique in identifying male breast carcinoma.
  • [MeSH-major] Adenocarcinoma / therapy. Breast Neoplasms, Male / pathology. Carcinoma, Papillary / pathology. Neoplasms, Second Primary / pathology. Prostatic Neoplasms / therapy
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Mammaglobin A. Neoplasm Metastasis. Neoplasm Proteins / analysis. Prostate-Specific Antigen / analysis. Uteroglobin / analysis

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):446-9 [8621225.001]
  • [Cites] Cancer Res. 1995 Mar 1;55(5):1002-5 [7866981.001]
  • [Cites] Pathology. 1997 Feb;29(1):2-6 [9094169.001]
  • [Cites] J Mol Med (Berl). 1997 Oct;75(10):758-61 [9383000.001]
  • [Cites] Indian J Pathol Microbiol. 1998 Jan;41(1):103-6 [9581085.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):498-509 [9690543.001]
  • [Cites] Acta Cytol. 1999 Sep-Oct;43(5):767-70 [10518128.001]
  • [Cites] Cancer. 1962 May-Jun;15:444-55 [14459407.001]
  • [Cites] Breast J. 2003 May-Jun;9(3):208-12 [12752629.001]
  • [Cites] Diagn Cytopathol. 2003 Jun;28(6):329-34 [12768640.001]
  • [Cites] Arch Pathol Lab Med. 1986 Mar;110(3):189-91 [3080975.001]
  • [Cites] Tumori. 1986 Feb 28;72(1):105-8 [3952817.001]
  • [Cites] Diagn Cytopathol. 1991;7(6):581-90 [1769286.001]
  • [Cites] Am J Epidemiol. 1992 Apr 1;135(7):734-48 [1350708.001]
  • [Cites] Int J Cancer. 1993 Jan 21;53(2):269-77 [8425764.001]
  • [Cites] Acta Cytol. 1993 Sep-Oct;37(5):721-4 [8362586.001]
  • [Cites] Diagn Cytopathol. 1994;10(4):336-41 [7924806.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):860-5 [8631025.001]
  • (PMID = 16548002.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108597
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 18
  • [Other-IDs] NLM/ NIHMS399894; NLM/ PMC3428056
  •  go-up   go-down


75. Bradbury PA, Zhai R, Hopkins J, Kulke MH, Heist RS, Singh S, Zhou W, Ma C, Xu W, Asomaning K, Ter-Minassian M, Wang Z, Su L, Christiani DC, Liu G: Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis. Carcinogenesis; 2009 May;30(5):793-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis.
  • We studied the association between four MMP polymorphisms within three MMP genes and esophageal adenocarcinoma (EA) risk and prognosis.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2002 Dec 10;102(5):526-9 [12432557.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2819-23 [12019159.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]
  • [Cites] Br J Cancer. 2003 Dec 1;89(11):2116-21 [14647147.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3b):2021-6 [15274394.001]
  • [Cites] J Biol Chem. 1996 May 31;271(22):13055-60 [8662692.001]
  • [Cites] Am J Gastroenterol. 1997 Feb;92(2):193-4 [9040189.001]
  • [Cites] J Pathol. 1998 Jul;185(3):256-61 [9771478.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5321-5 [9850057.001]
  • [Cites] Ann N Y Acad Sci. 1998 Oct 23;857:180-93 [9917841.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):481-6 [15528217.001]
  • [Cites] Breast Cancer Res. 2005;7(4):R506-12 [15987457.001]
  • [Cites] Carcinogenesis. 2006 May;27(5):1024-9 [16311244.001]
  • [Cites] World J Gastroenterol. 2007 Feb 7;13(5):676-82 [17278189.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1254-8 [17264068.001]
  • [Cites] BMC Cancer. 2007;7:187 [17919326.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3216-22 [18483390.001]
  • [Cites] Cancer Causes Control. 2008 Dec;19(10):1077-83 [18478337.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Circ Res. 2000 May 12;86(9):998-1003 [10807873.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Aug;15(8):1087-100 [11472311.001]
  • [Cites] Br J Cancer. 2001 Aug 3;85(3):383-92 [11487270.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7825-9 [11691799.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Apr 15;167(8):1083-9 [12522030.001]
  • (PMID = 19321798.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA074386
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.65 / Matrix Metalloproteinase 12; EC 3.4.24.7 / Matrix Metalloproteinase 1
  • [Other-IDs] NLM/ PMC2675656
  •  go-up   go-down


76. Farhat F, Fakhruddine N: A case of synchronous relapse of breast cancer and uterine müllerian adenosarcoma post tamoxifen in a premenopausal woman. Eur J Gynaecol Oncol; 2008;29(1):95-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of synchronous relapse of breast cancer and uterine müllerian adenosarcoma post tamoxifen in a premenopausal woman.
  • PURPOSE & METHODS: We report a case of a 42-year-old multigravida, premenopausal woman with breast carcinoma, who presented after four years of use of adjuvant tamoxifen with synchronous liver, bone, and lung metastasis of breast cancer with müllerian adenosarcoma.
  • CONCLUSION: Our case is the only one reported in the literature with synchronous relapse of breast adenocarcinoma and a Müllerian adenosarcoma.
  • [MeSH-major] Adenosarcoma / pathology. Breast Neoplasms / drug therapy. Mixed Tumor, Mullerian / pathology. Neoplasm Recurrence, Local / complications. Tamoxifen / adverse effects. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18386476.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 12
  •  go-up   go-down


77. Matsuno Y, Deguchi J, Hosoya T, Hirasawa Y, Hirobe C, Shiro M, Morita H: Sucutiniranes C-F, cassane-type diterpenes from Bowdichia nitida. J Nat Prod; 2009 May 22;72(5):976-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sucutiniranes E (5) and F (6) were moderately cytotoxic against human blood premyelocytic leukemia (HL-60), breast adenocarcinoma (MCF-7), and colon cancer (HCT-116) cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19361174.001).
  • [ISSN] 1520-6025
  • [Journal-full-title] Journal of natural products
  • [ISO-abbreviation] J. Nat. Prod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Diterpenes
  •  go-up   go-down


78. Marcinová M, Lukco D, Krajníková S, Vrzgula A: [Axillary dissection in the surgical management of invasive breast cancer in postmenopausal female patients]. Rozhl Chir; 2010 Nov;89(11):666-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Axillary dissection in the surgical management of invasive breast cancer in postmenopausal female patients].
  • The breast cancer is the most commonly diagnosed cancer worldwide and the leading cause of cancer mortality of women over 55 years of age.
  • The progress of breast cancer is less aggressive in erderly women and the response to the adjuvant therapy is different too.
  • According to the retrospective analysis the authors discussed the up-to-date role of axillary dissection in selected groups of postmenopauzal women with the early breast cancer (T1N0M0) and its impact on postoperative quality of everyday life.
  • [MeSH-major] Breast Neoplasms / surgery. Lymph Node Excision
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Axilla. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Carcinoma, Lobular / pathology. Carcinoma, Lobular / surgery. Female. Humans. Lymphatic Metastasis. Middle Aged. Postmenopause


79. Serrano Vicente J, Infante de la Torre JR, Domínguez Grande ML, García Bernardo L, Durán Barquero C, Rayo Madrid JI, Sánchez Sánchez R, Correa Antúnez MI, Amaya Lozano JL, Conde Martín AF: [Optimization of sentinel lymph node biopsy in breast cancer by intraoperative axillary palpation]. Rev Esp Med Nucl; 2010 Jan-Feb;29(1):8-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Optimization of sentinel lymph node biopsy in breast cancer by intraoperative axillary palpation].
  • [Transliterated title] Optimización de la biopsia selectiva de ganglio centinela en el cáncer de mama mediante palpación axilar intraoperatoria.
  • INTRODUCTION: Sentinel node biopsy (SNB) by radioisotopes is a widely accepted and reliable surgical method for staging breast cancer in patients with unknown positive axillary lymph nodes involvement.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / surgery. Lymph Node Excision. Lymphatic Metastasis / diagnosis. Palpation / methods. Sentinel Lymph Node Biopsy / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier España, S.L. y SEMNIM. All rights reserved.
  • (PMID = 20015577.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals
  •  go-up   go-down


80. Jarzab M, Rózanowski P, Kowalska M, Zebracka J, Rudnicka L, Stobiecka E, Jarzab B, Stachura J, Pawlega J: Optimization of the method of RNA isolation from paraffin blocks to assess gene expression in breast cancer. Pol J Pathol; 2008;59(2):85-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimization of the method of RNA isolation from paraffin blocks to assess gene expression in breast cancer.
  • The aim of the present study was to implement into practice a method of RNA isolation from formalin-fixed and paraffin-embedded (FFPE) breast carcinoma samples collected during routine surgical and histopathological procedure, to further employ it in expression analysis by Q-PCR.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. RNA, Neoplasm / isolation & purification

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Biospecimen Research Database. Biospecimen Research Database .
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18669173.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Fixatives; 0 / RNA, Neoplasm; 0 / Reagent Kits, Diagnostic; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


81. Aghi M, Kiehl TR, Brisman JL: Breast adenocarcinoma metastatic to epidural cervical spine meningioma: case report and review of the literature. J Neurooncol; 2005 Nov;75(2):149-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast adenocarcinoma metastatic to epidural cervical spine meningioma: case report and review of the literature.
  • We report a case of breast carcinoma metastatic to an epidural cervical meningioma, summarize the literature on metastases to central nervous system meningiomas, and suggest a possible mechanism.
  • Because of concern that the fracture and epidural lesion might represent metastases, we performed a metastatic work-up, which revealed a right breast mass.
  • Intraoperative frozen section revealed mixed meningioma and breast adenocarcinoma.
  • Mechanisms of this unusual process likely include meningiomas' vascularity, meningiomas' slow growth providing nutrient availability, and perhaps, as suggested by our analysis, E-cadherin expression by both meningiomas and breast cancer.
  • Metastasis to meningioma must be considered in an epidural spinal lesion in all patients with a known malignancy, with surgical aggressiveness tailored to the intraoperative pathologic diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Cervical Vertebrae / pathology. Meningioma / diagnosis. Meningioma / secondary. Spinal Cord Neoplasms / diagnosis. Spinal Cord Neoplasms / secondary


82. Lucas JM, True L, Hawley S, Matsumura M, Morrissey C, Vessella R, Nelson PS: The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma. J Pathol; 2008 Jun;215(2):118-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
  • Two other members of the TTSP family, matriptase and hepsin, are over-expressed in prostate adenocarcinoma and mechanistically influence cancer cell invasion and metastasis.
  • TMPRSS2 protein is abundantly expressed in the prostate, with low levels in the epithelia of the colon, stomach, epididymis and breast.
  • [MeSH-major] Adenocarcinoma / chemistry. Adenocarcinoma / secondary. Gene Expression Regulation, Neoplastic. Prostatic Neoplasms / chemistry. Serine Endopeptidases / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 18338334.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01CA85859; United States / NCI NIH HHS / CA / P50CA97186; United States / NIDDK NIH HHS / DK / R01DK069690; United States / NIDDK NIH HHS / DK / R01DK65204
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / TMPRSS2 protein, human
  •  go-up   go-down


83. Wakamatsu S, Mitsuyama S, Nanba K, Nishimura R, Sagara Y, Tanaka M, Tamaki N, Koga T, Tamura K: Adjuvant therapy for breast cancer in Kyushu. Breast Cancer; 2006;13(3):308-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant therapy for breast cancer in Kyushu.
  • BACKGROUND: There is lack of information on the present status of adjuvant therapy for breast cancer in Kyushu.
  • Therefore, the Kyushu Breast Cancer Study Group (KBC-SG) started registering newly diagnosed breast cancer patients who were to receive adjuvant therapy.
  • METHODS: During a period from 2001 to 2003, institutions participating in KBC-SG registered new patients who underwent curative surgical treatment for breast cancer to the registration office.
  • Adjuvant radiation therapy was also given to only 20% of the patients in Kyushu, which might be fewer than the report by the Japanese Breast Cancer Society.
  • Based on these data, the KBC-SG will continue cooperative studies to improve the quality of adjuvant treatment for early breast cancer.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / radiotherapy. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / radiotherapy. Carcinoma, Ductal, Breast / surgery. Chemotherapy, Adjuvant. Female. Humans. Japan. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Radiotherapy, Adjuvant. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Breast Cancer. 2006;13(4):386. Nishimura, Kiyoshi [corrected to Nishimura, Reiki]
  • (PMID = 16929126.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Receptors, Estrogen; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


84. Martín-Ondarza C, Gil-Moreno A, Torres-Cuesta L, García A, Eyzaguirre F, Díaz-Feijoo B, Xercavins J: Endometrial cancer in polyps: a clinical study of 27 cases. Eur J Gynaecol Oncol; 2005;26(1):55-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three breast cancer patients were currently given tamoxifen.
  • Metrorrhagia was the presenting symptom in 74% of cases, although 22% of patients were asymptomatic at the time of diagnosis.
  • Diagnosis was made by aspiration-biopsy in 13 patients and by hysteroscopic endometrial sampling in 13 (in one patient endometrial carcinoma was incidentally found in the surgical specimen).
  • [MeSH-minor] Adenocarcinoma, Papillary / epidemiology. Adenocarcinoma, Papillary / etiology. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / ultrasonography. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / etiology. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / ultrasonography. Carcinoma, Endometrioid / epidemiology. Carcinoma, Endometrioid / etiology. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / ultrasonography. Female. Humans. Medical Records. Middle Aged. Prevalence. Retrospective Studies. Risk Factors. Spain / epidemiology

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755002.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


85. Sotgia F, Rui H, Bonuccelli G, Mercier I, Pestell RG, Lisanti MP: Caveolin-1, mammary stem cells, and estrogen-dependent breast cancers. Cancer Res; 2006 Nov 15;66(22):10647-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveolin-1, mammary stem cells, and estrogen-dependent breast cancers.
  • Estrogen exposure is considered a significant risk factor for breast cancer development.
  • Estrogen receptor (ER) alpha is expressed at low levels in normal epithelia, and its expression is dramatically up-regulated as transformation progresses during mammary hyperplasia and adenocarcinoma development.
  • Interestingly, Cav-1 dominant-negative mutations are exclusively found in ERalpha-positive breast cancer samples.
  • [MeSH-major] Adult Stem Cells / pathology. Breast Neoplasms / genetics. Caveolin 1 / genetics. Mammary Glands, Animal / pathology. Mammary Glands, Human / pathology. Neoplasms, Hormone-Dependent / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17108100.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA80250; United States / NCI NIH HHS / CA / R01CA93596; United States / NCI NIH HHS / CA / R01CA98779
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caveolin 1; 0 / Estrogen Receptor alpha
  • [Number-of-references] 41
  •  go-up   go-down


86. Kommareddy S, Amiji M: Biodistribution and pharmacokinetic analysis of long-circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice. J Pharm Sci; 2007 Feb;96(2):397-407
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biodistribution and pharmacokinetic analysis of long-circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice.
  • The objective of the present study was to modify thiolated gelatin nanoparticles with poly(ethylene glycol) (PEG) chains and examine their long circulating and tumor-targeting properties in vivo in an orthotopic a human breast adenocarcinoma xenograft model.
  • The in vivo long-circulating potential, biodistribution and passive tumor targeting of the controls, and PEG-modified thiolated gelatin nanoparticles were evaluated by injecting indium-111 (111In)-labeled nanoparticles into breast tumor (MDA-MB-435)-bearing nude mice.
  • [MeSH-major] Breast Neoplasms / metabolism. Gelatin / chemistry. Nanoparticles. Polyethylene Glycols / chemistry. Sulfhydryl Compounds / chemistry

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI caNanoLab Data Portal. supplemental materials - caNanoLab samples curated from the publication .
  • Hazardous Substances Data Bank. GELATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • (PMID = 17075865.001).
  • [ISSN] 0022-3549
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / EB-002027; United States / NCI NIH HHS / CA / R01-CA095522
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indium Radioisotopes; 0 / Sulfhydryl Compounds; 30IQX730WE / Polyethylene Glycols; 9000-70-8 / Gelatin
  •  go-up   go-down


87. Wong SY, Crowley D, Bronson RT, Hynes RO: Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer. Clin Exp Metastasis; 2008;25(2):109-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer.
  • To test the role of endogenous SPARC in tumorigenesis directly, we examined cancer progression and metastasis in SPARC(+/-) and SPARC(-/-) mice using two separate transgenic mouse tumor models: transgenic adenocarcinoma of the mouse prostate (TRAMP) and murine mammary tumor virus-polyoma middle T (MMTV-PyMT).

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5B):4199-202 [10628375.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1140-9 [10741745.001]
  • [Cites] Matrix Biol. 2001 Jan;19(8):816-27 [11223341.001]
  • [Cites] J Clin Invest. 2001 Apr;107(7):785-90 [11285293.001]
  • [Cites] J Clin Invest. 2001 May;107(9):1049-54 [11342565.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):609-22 [11485919.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):5974-8 [11507037.001]
  • [Cites] Nature. 2001 Aug 23;412(6849):822-6 [11518967.001]
  • [Cites] Genome Biol. 2001;2(8):RESEARCH0032 [11532216.001]
  • [Cites] J Urol. 2001 Dec;166(6):2495-9 [11696817.001]
  • [Cites] J Histochem Cytochem. 2002 Jan;50(1):1-10 [11748289.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] J Clin Invest. 2003 Feb;111(4):487-95 [12588887.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]
  • [Cites] J Biol Chem. 2003 Oct 3;278(40):39044-50 [12885781.001]
  • [Cites] Mol Biol Cell. 2003 Oct;14(10):3977-88 [14517312.001]
  • [Cites] Bioinformatics. 2003 Nov 1;19(16):2065-71 [14594711.001]
  • [Cites] J Exp Med. 2003 Nov 17;198(10):1475-85 [14610043.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6 [14711987.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] Mol Cancer Res. 2004 Apr;2(4):215-24 [15140943.001]
  • [Cites] J Cell Biochem. 2004 Jul 1;92(4):679-90 [15211566.001]
  • [Cites] J Invest Dermatol. 2004 Sep;123(3):592-9 [15304102.001]
  • [Cites] Invest Urol. 1979 Jul;17(1):16-23 [447482.001]
  • [Cites] J Cell Biol. 1989 Jul;109(1):341-56 [2745554.001]
  • [Cites] Mol Cell Biol. 1992 Mar;12(3):954-61 [1312220.001]
  • [Cites] J Cell Biol. 1993 Jun;121(6):1433-44 [8509459.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] Mol Biol Cell. 1995 Mar;6(3):327-43 [7612967.001]
  • [Cites] Nat Med. 1997 Feb;3(2):171-6 [9018235.001]
  • [Cites] J Cell Physiol. 1997 Dec;173(3):327-34 [9369945.001]
  • [Cites] Prostate. 1998 Feb 15;34(3):169-74 [9492844.001]
  • [Cites] J Cell Biochem. 1998 Sep 15;70(4):543-52 [9712151.001]
  • [Cites] J Biol Chem. 1998 Nov 6;273(45):29635-40 [9792673.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1998 Dec;39(13):2674-80 [9856777.001]
  • [Cites] J Pathol. 1999 Sep;189(1):46-52 [10451487.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4453-7 [10485497.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Br J Cancer. 2004 Nov 29;91(11):1924-30 [15558074.001]
  • [Cites] Int J Cancer. 2005 Feb 20;113(5):789-97 [15499618.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1492-502 [15902309.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7370-7 [16103089.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9789-98 [16267000.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):310-6 [16052522.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7516-23 [16885349.001]
  • [Cites] Oncogene. 2007 Jul 5;26(31):4513-22 [17260013.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12784-9 [17640904.001]
  • [Cites] Gut. 2007 Oct;56(10):1410-4 [17299058.001]
  • [Cites] Curr Protoc Immunol. 2001 Nov;Chapter 20:Unit 20.5 [18432778.001]
  • (PMID = 18058030.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA017007; United States / NCI NIH HHS / CA / R01CA17007; United States / NCI NIH HHS / CA / U54 CA112967; United States / NCI NIH HHS / CA / R01 CA017007-30; United States / NCI NIH HHS / CA / U54-CA112967; United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / Osteonectin; 9007-34-5 / Collagen
  • [Other-IDs] NLM/ NIHMS345773; NLM/ PMC3252392
  •  go-up   go-down


88. Kazakov DV, Requena L, Kutzner H, Fernandez-Figueras MT, Kacerovska D, Mentzel T, Schwabbauer P, Michal M: Morphologic diversity of syringocystadenocarcinoma papilliferum based on a clinicopathologic study of 6 cases and review of the literature. Am J Dermatopathol; 2010 Jun;32(4):340-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Syringocystadenocarcinoma papilliferum invariably occurred in association with syringocystadenoma papilliferum and presented as an in situ adenocarcinoma and/or invasive adenocarcinoma.
  • Variable present features included pagetoid migration of the neoplastic cells, dirty necrosis, mucinous ductal metaplasia, and ductal changes analogous to those seen in the breast.
  • Its association with the benign counterpart and ductal changes suggests a transformation that may involve usual ductal hyperplasia-atypical ductal hyperplasia-(ductal) adenocarcinoma in situ-invasive adenocarcinoma pathway.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20216201.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


89. Shigematsu H, Andou A, Matsuo K: Pulmonary tumor embolism. J Thorac Oncol; 2009 Jun;4(6):777; author reply 777-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / secondary. Fibrin Fibrinogen Degradation Products / metabolism. Heart Failure / etiology. Lung Neoplasms / secondary. Neoplastic Cells, Circulating / pathology. Pulmonary Embolism / complications. Pulmonary Heart Disease / etiology
  • [MeSH-minor] Breast Neoplasms / pathology. Diagnosis, Differential. Dyspnea / diagnosis. Dyspnea / etiology. Female. Humans. Lymphangitis / diagnosis. Lymphangitis / etiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Thorac Oncol. 2008 Dec;3(12):1482-3 [19057276.001]
  • (PMID = 19461409.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrin Fibrinogen Degradation Products; 0 / fibrin fragment D
  •  go-up   go-down


90. Pinto-Correia AL, Sousa H, Fragoso M, Moreira-Dias L, Lopes C, Medeiros R, Dinis-Ribeiro M: Gastric cancer in a Caucasian population: role of pepsinogen C genetic variants. World J Gastroenterol; 2006 Aug 21;12(31):5033-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Our results revealed that Allele 6 carriers seemed to have protection against the development of any gastric lesion (OR = 0.34; P<0.001), non-dysplastic lesions associated with gastric adenocarcinoma such as atrophy or intestinal metaplasia (OR = 0.28; P<0.001) or invasive GC (OR = 0.39; P = 0.004).

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1988 Feb 15;41(2):184-97 [3338870.001]
  • [Cites] Gene. 2004 Oct 27;341:1-17 [15474284.001]
  • [Cites] Jpn J Cancer Res. 1989 Feb;80(2):111-4 [2498245.001]
  • [Cites] Trends Genet. 1989 Dec;5(12):391 [2623762.001]
  • [Cites] Adv Exp Med Biol. 1991;306:95-9 [1812765.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6735-40 [1458460.001]
  • [Cites] Eur J Cancer Prev. 1995 Oct;4(5):389-417 [7496328.001]
  • [Cites] Ann Hum Genet. 1997 Mar;61(Pt 2):93-7 [9177116.001]
  • [Cites] Eur J Cancer. 1997 Jun;33(7):1075-107 [9376190.001]
  • [Cites] Gut. 1997 Oct;41(4):469-74 [9391244.001]
  • [Cites] Hum Genet. 1997 Dec;101(2):201-4 [9402969.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Neoplasia. 2004 Sep-Oct;6(5):449-56 [15548353.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):481-8 [15718248.001]
  • [Cites] World J Gastroenterol. 2005 May 7;11(17):2545-8 [15849808.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jul 1;160(1):49-54 [15949570.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 26;334(2):588-92 [16009345.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Feb 3;340(1):256-62 [16364249.001]
  • [Cites] Eur J Cancer Prev. 2006 Aug;15(4):362-6 [16835507.001]
  • [Cites] Breast J. 2002 Jul-Aug;8(4):226-9 [12100115.001]
  • [Cites] Eur J Cancer Prev. 2002 Aug;11(4):343-50 [12195160.001]
  • [Cites] World J Gastroenterol. 2003 Jan;9(1):50-3 [12508350.001]
  • [Cites] Cell Physiol Biochem. 2003;13(5):301-8 [14586174.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(17):2507-20 [14602137.001]
  • [Cites] Prostate. 2004 May 15;59(3):268-74 [15042602.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Apr 15;150(2):116-21 [15066318.001]
  • [Cites] Eur J Cancer Prev. 2004 Jun;13(3):177-81 [15167216.001]
  • [Cites] Angiogenesis. 2004;7(1):53-8 [15302996.001]
  • [Cites] Nucleic Acids Res. 1988 Oct 11;16(19):9372 [2902599.001]
  • (PMID = 16937501.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 61536-72-9 / Pepsinogen C; 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC4087408
  •  go-up   go-down


91. Sakurai N, Nakagawa-Goto K, Ito J, Sakurai Y, Nakanishi Y, Bastow KF, Cragg G, Lee KH: Cytotoxic Alangium alkaloids from Alangium longiflorum. Phytochemistry; 2006 May;67(9):894-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biological evaluation showed that 2, 10-O-demethylcephaeline, exhibited potent cytotoxic activity against human lung carcinoma (A549) and breast adenocarcinoma (MCF-7) with ED(50) values of 0.013 and 0.062 microM, respectively.
  • [MeSH-minor] Breast Neoplasms / drug therapy. Cell Line, Tumor. Drug Screening Assays, Antitumor. Humans. Lung Neoplasms / drug therapy. Molecular Structure. Plant Bark / chemistry. Stereoisomerism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16530796.001).
  • [ISSN] 0031-9422
  • [Journal-full-title] Phytochemistry
  • [ISO-abbreviation] Phytochemistry
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-17625
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 10-O-demethylcephaeline; 0 / Alkaloids; 0 / Terpenes; 0 / Tetrahydroisoquinolines; 0 / isocephaeline
  •  go-up   go-down


92. Khodarev NN, Pitroda SP, Beckett MA, MacDermed DM, Huang L, Kufe DW, Weichselbaum RR: MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res; 2009 Apr 1;69(7):2833-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer.
  • The Mucin 1 (MUC1) oncoprotein is aberrantly overexpressed in diverse human malignancies including breast and lung cancer.
  • A set of experimentally derived MUC1-induced genes associated with tumorigenesis was applied to the analysis of breast and lung adenocarcinoma cancer databases.
  • A 35-gene MUC1-induced tumorigenesis signature predicts significant decreases in both disease-free and overall survival in patients with breast (n=295) and lung (n=442) cancers.
  • The data show that the MUC1 oncoprotein contributes to the regulation of genes that are highly predictive of clinical outcome in breast and lung cancer patients.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Biotechniques. 2002 Feb;32(2):316, 318, 320 [11848408.001]
  • [Cites] Genomics. 2003 Feb;81(2):202-9 [12620398.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):6107-10 [12955090.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35458-64 [12826677.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1714-9 [14755057.001]
  • [Cites] Cancer Cell. 2004 Feb;5(2):163-75 [14998492.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):20607-12 [14999001.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):553-63 [15380592.001]
  • [Cites] Hybridoma. 1984 Fall;3(3):223-32 [6094338.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Apr;85(7):2320-3 [2895474.001]
  • [Cites] Cancer Res. 1989 Dec 15;49(24 Pt 1):6966-71 [2582438.001]
  • [Cites] J Biol Chem. 1992 Mar 25;267(9):6171-7 [1556125.001]
  • [Cites] Nature. 1998 Jul 16;394(6690):287-91 [9685160.001]
  • [Cites] Cancer Cell. 2005 Feb;7(2):167-78 [15710329.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3738-43 [15701700.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3146-54 [15833844.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10413-22 [16288032.001]
  • [Cites] Nat Struct Mol Biol. 2006 Jan;13(1):71-6 [16369486.001]
  • [Cites] Mol Cell. 2006 Jan 20;21(2):295-305 [16427018.001]
  • [Cites] Trends Cell Biol. 2006 Sep;16(9):467-76 [16904320.001]
  • [Cites] BMC Cancer. 2006;6:220 [16953875.001]
  • [Cites] Int J Cancer. 2007 Jun 15;120(12):2643-9 [17294451.001]
  • [Cites] Int J Oncol. 2007 Sep;31(3):671-7 [17671696.001]
  • [Cites] Sci Signal. 2008;1(27):pe35 [18612140.001]
  • [Cites] Nat Med. 2008 Aug;14(8):822-7 [18641660.001]
  • (PMID = 19318547.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA097098; United States / NCI NIH HHS / CA / R01 CA1114231; United States / NCI NIH HHS / CA / R01 CA97098; United States / NCI NIH HHS / CA / R01 CA111423-01A1; United States / NCI NIH HHS / CA / R01 CA111423; United States / NCI NIH HHS / CA / CA111423-01A1; United States / NCI NIH HHS / CA / R01 CA097098-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MUC1 protein, human; 0 / Mucin-1
  • [Other-IDs] NLM/ NIHMS263646; NLM/ PMC3034477
  •  go-up   go-down


93. Rieck GC, Freites ON, Williams S: Is tamoxifen associated with high-risk endometrial carcinomas? A retrospective case series of 196 women with endometrial cancer. J Obstet Gynaecol; 2005 Jan;25(1):39-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 20 patients had a history of breast cancer being treated with adjuvant tamoxifen therapy and developed subsequently endometrial cancer.
  • The histology in women who had not taken tamoxifen showed: adenocarcinoma (97.1%), 1.7% had mixed mullerian tumour.
  • Women in the tamoxifen-treated group had: adenocarcinoma (85%), sarcoma (5%), mixed mullerian tumour (5%).
  • [MeSH-minor] Adenocarcinoma / chemically induced. Adenocarcinoma / epidemiology. Adult. Aged. Aged, 80 and over. Breast Neoplasms / drug therapy. Chemotherapy, Adjuvant. Female. Hospitals, General. Humans. Middle Aged. Mixed Tumor, Mullerian / chemically induced. Mixed Tumor, Mullerian / epidemiology. Prognosis. Retrospective Studies. Risk Factors. Sarcoma / chemically induced. Sarcoma / epidemiology

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16147692.001).
  • [ISSN] 0144-3615
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


94. Monteiro MJ, Herold J, Burkill G: Unusual presentation of metastatic breast carcinoma. Br J Oral Maxillofac Surg; 2009 Jan;47(1):84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of metastatic breast carcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / pathology. Skull Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18692944.001).
  • [ISSN] 1532-1940
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Scotland
  •  go-up   go-down


95. Caraglia M, Santini D, Marra M, Vincenzi B, Tonini G, Budillon A: Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer; 2006 Mar;13(1):7-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bone metastases are common in patients with many types of cancer, especially breast and prostate cancer--in which the incidence is approximately 70% among patients with advanced metastatic disease.
  • Aminobisphosphonates (NBPs) have entered clinical practice in the treatment of bone metastases from several neoplasms, including breast and prostate adenocarcinoma, as a result of their anti-resorption properties.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16601276.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphosphonates
  • [Number-of-references] 143
  •  go-up   go-down


96. Song SH, Lee JK, Saw HS, Choi SY, Koo BH, Kim A, Yeom BW, Kim I: Peutz-Jeghers Syndrome with multiple genital tract tumors and breast cancer: a case report with a review of literatures. J Korean Med Sci; 2006 Aug;21(4):752-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peutz-Jeghers Syndrome with multiple genital tract tumors and breast cancer: a case report with a review of literatures.
  • Her previous medical history was PJS and breast cancer.
  • An ovarian sex cord tumor with annular tubules was incidentally diagnosed together with a minimal deviation adenocarcinoma of the uterine cervix and mucinous metaplasia of both the Fallopian tubal mucosa and the endometrium.
  • Although the cases of multiple genital tract tumors with PJS has rarely been reported, the present case appears to be the first in Korea in which the PJS syndrome was complicated by multiple genital tract tumors and infiltrating carcinoma of the breast.
  • The clinical significance of the multiple genital tract tumors and breast cancer associated with PJS is reviewed.
  • [MeSH-major] Breast Neoplasms / pathology. Ovarian Neoplasms / pathology. Peutz-Jeghers Syndrome / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / pathology. Adult. Carcinoma, Ductal, Breast / complications. Carcinoma, Ductal, Breast / pathology. Endometrium / pathology. Fallopian Tubes / pathology. Female. Humans. Korea. Metaplasia. Sex Cord-Gonadal Stromal Tumors / complications. Sex Cord-Gonadal Stromal Tumors / pathology


97. Obenauer S, Sohns C, Werner C, Grabbe E: Computer-aided detection in full-field digital mammography: detection in dependence of the BI-RADS categories. Breast J; 2006 Jan-Feb;12(1):16-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The object of this study was to determine the performance of a computer-aided detection system in full-field digital mammography (Senographe 2000D, General Electric, Buc, France) in detecting carcinomas in breasts in dependence of the initial Breast Imaging Reporting and Data System (BI-RADS) categories.
  • [MeSH-major] Breast Neoplasms / radiography. Mammography / standards. Radiographic Image Interpretation, Computer-Assisted / standards
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radiography. Adult. Aged. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / radiography. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / radiography. Carcinoma, Lobular / pathology. Carcinoma, Lobular / radiography. Carcinoma, Medullary / pathology. Carcinoma, Medullary / radiography. Carcinoma, Papillary / pathology. Carcinoma, Papillary / radiography. False Positive Reactions. Female. Hemangiosarcoma / pathology. Hemangiosarcoma / radiography. Humans. Middle Aged. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16409582.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Koo CL, Kok LF, Lee MY, Wu TS, Cheng YW, Hsu JD, Ruan A, Chao KC, Han CP: Scoring mechanisms of p16INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. J Transl Med; 2009;7:25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Endometrial Neoplasms / metabolism. Uterine Cervical Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Biopsy. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Protein Array Analysis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 2001 May;67(1):61-70 [11518467.001]
  • [Cites] Arch Gynecol Obstet. 2009 Sep;280(3):405-13 [19153755.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):4-10 [11781516.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):11-5 [11781517.001]
  • [Cites] Radiology. 2002 May;223(2):410-6 [11997546.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jul;21(3):217-23 [12068166.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1323-7 [12389040.001]
  • [Cites] Virchows Arch. 2003 Mar;442(3):271-7 [12647218.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jul;22(3):231-5 [12819388.001]
  • [Cites] J Histochem Cytochem. 2003 Oct;51(10):1291-7 [14500697.001]
  • [Cites] Curr Treat Options Oncol. 2004 Apr;5(2):119-27 [14990206.001]
  • [Cites] Semin Nucl Med. 1978 Oct;8(4):283-98 [112681.001]
  • [Cites] Clin Chem. 1993 Apr;39(4):561-77 [8472349.001]
  • [Cites] Pathol Res Pract. 1993 Sep;189(8):862-6 [8302707.001]
  • [Cites] Am J Clin Pathol. 1995 Jan;103(1):41-7 [7817943.001]
  • [Cites] Nat Genet. 1995 May;10(1):114-6 [7647780.001]
  • [Cites] Int J Cancer. 1998 Feb 20;79(1):61-5 [9495360.001]
  • [Cites] Virchows Arch. 1999 Jan;434(1):23-8 [10071231.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):52-68 [15613856.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1497-504 [16224217.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jul;130(7):1026-30 [16831029.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1091-100 [16648864.001]
  • [Cites] Mod Pathol. 2006 Oct;19(10):1310-6 [16799478.001]
  • [Cites] Clinics (Sao Paulo). 2006 Oct;61(5):417-24 [17072439.001]
  • [Cites] Actas Urol Esp. 2006 Sep;30(8):754-62 [17078572.001]
  • [Cites] Ann Surg Oncol. 2006 Dec;13(12):1633-44 [17013685.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):306-13 [17242700.001]
  • [Cites] J Negat Results Biomed. 2007;6:6 [17459164.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10686-93 [18006810.001]
  • [Cites] J Transl Med. 2007;5:54 [17971233.001]
  • [Cites] Arch Pathol Lab Med. 2008 Mar;132(3):402-23 [18318583.001]
  • [Cites] J Transl Med. 2008;6:31 [18559092.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:25 [18673574.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):1-3 [11781515.001]
  • (PMID = 19366452.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16
  • [Other-IDs] NLM/ PMC2672079
  •  go-up   go-down


99. Ahmed M, Lukyanov AN, Torchilin V, Tournier H, Schneider AN, Goldberg SN: Combined radiofrequency ablation and adjuvant liposomal chemotherapy: effect of chemotherapeutic agent, nanoparticle size, and circulation time. J Vasc Interv Radiol; 2005 Oct;16(10):1365-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the effects of liposomal chemotherapeutic agent, nanoparticle size, and liposome circulation time on tissue coagulation and intratumoral drug uptake when radiofrequency (RF) ablation is combined with adjuvant intravenous liposomal chemotherapy in an animal breast tumor model.
  • MATERIALS AND METHODS: Ninety-one R3230 mammary adenocarcinoma nodules were implanted in 48 Fischer rats.
  • [MeSH-major] Adenocarcinoma / therapy. Antibiotics, Antineoplastic / therapeutic use. Catheter Ablation. Doxorubicin / therapeutic use. Mammary Neoplasms, Experimental / therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16221908.001).
  • [ISSN] 1051-0443
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA87992-01A1
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


100. Chandanos E, Lindblad M, Rubio CA, Jia C, Warner M, Gustafsson JA, Lagergren J: Tamoxifen exposure in relation to gastric adenocarcinoma development. Eur J Cancer; 2008 May;44(7):1007-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tamoxifen exposure in relation to gastric adenocarcinoma development.
  • Epidemiological research has indicated that the anti-oestrogen tamoxifen, used in breast cancer therapy, may increase the risk of gastric adenocarcinoma of the intestinal but not of the diffuse type.
  • The study participants comprised women in the county of Stockholm who in the Swedish Cancer Register were first recorded with breast cancer and subsequently gastric cancer during the period January 1958-August 2005.
  • Tumour material was reviewed histologically to verify gastric adenocarcinoma diagnosis and classify these cancers into intestinal or diffuse type.
  • Amongst 68 women with verified gastric adenocarcinoma, 30 had been treated with tamoxifen and 38 not.
  • The intestinal type of gastric adenocarcinoma was not more frequent amongst tamoxifen users (27%) than amongst non-users (34%) (p=0.601).
  • There were no material differences between the tamoxifen groups regarding distribution of any of the three ERs of the intestinal adenocarcinoma specimens.
  • Tamoxifen users had a shorter latency between breast cancer and gastric adenocarcinoma (4 versus 13 years) which was similar in the intestinal and diffuse types.
  • This study does not support the hypothesis that tamoxifen increases the isolated risk of the intestinal type, but it indicates that tamoxifen use might accelerate the tumour progression or increase the overall risk of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Stomach Neoplasms / chemically induced. Tamoxifen / adverse effects

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18394879.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down






Advertisement